

Draft Screening Assessment

Substances Identified as Being of Low Concern Using the Ecological Risk Classification of Inorganic Substances and Biomonitoring or Rapid Screening Science Approaches

**Environment and Climate Change Canada
Health Canada**

February 2022

Synopsis

Pursuant to section 74 of the *Canadian Environmental Protection Act, 1999* (CEPA), the Minister of the Environment and the Minister of Health have conducted a screening assessment of 34 substances. These substances were identified as priorities for assessment as they met categorization criteria under subsection 73(1) of CEPA. The Chemical Abstracts Service Registry Numbers (CAS RN¹), *Domestic Substances List* (DSL) names, and common names of these substances are listed in the Appendix A, Table A-1.

According to information submitted in response to a CEPA section 71 survey, no consumer uses were identified for the majority of substances. Some of these substances may be used in the manufacture of food packaging materials while others are present in products available to consumers including drugs, natural health products, cosmetics, sealants, lubricants and greases, paper products, paints and coatings, batteries, water treatment products, pesticides, and disinfectants. Industrial uses include use as paint additives, processing aids, lubricants, viscosity adjusters, desiccants, pH adjusters, adhesives and sealants, and intermediates.

The ecological risks of the substances in this assessment were characterized using the Ecological Risk Classification of inorganic substances (ERC-I) which is a risk-based approach that employs multiple metrics for both hazard and exposure, with weighted consideration of multiple lines of evidence for determining risk classification. Hazard characterization in ERC-I included a survey of published predicted no-effect concentrations (PNEC) and water quality guidelines, and the derivation of new PNEC values when required. Exposure profiling considered two approaches: predictive modelling using a generic near-field exposure model for each substance, and an analysis of measured concentrations collected by federal and provincial water quality monitoring programs using metal concentrations as a conservative indicator of exposure for individual substances. Modelled and measured predicted environmental concentrations were compared to PNECs, and multiple statistical metrics were computed and compared to decision criteria to classify the potential to cause harm to the environment. Based on the outcome of the ERC-I analysis, the 34 substances in this assessment are considered unlikely to be causing ecological harm.

¹ The Chemical Abstracts Service Registry Number (CAS RN) is the property of the American Chemical Society, and any use or redistribution, except as required in supporting regulatory requirements and/or for reports to the Government of Canada when the information and the reports are required by law or administrative policy, is not permitted without the prior written permission of the American Chemical Society.

Considering all available lines of evidence presented in this draft screening assessment, there is low risk of harm to the environment from the 34 substances in this assessment. It is proposed to conclude that these substances do not meet the criteria under paragraphs 64(a) or (b) of CEPA as they are not entering the environment in a quantity or concentration or under conditions that have or may have an immediate or long-term harmful effect on the environment or its biological diversity or that constitute or may constitute a danger to the environment on which life depends.

The human health risks of the substances in this assessment based on current levels of exposure were characterized using one of three science approaches: Biomonitoring-based Approach 1, Biomonitoring-based Approach 2, or the Rapid Screening of Substances with Limited General Population Exposure Approach. The Biomonitoring-based Approach 1 is a qualitative science approach used to identify substances with limited exposure based on substances or moieties measured in the Canadian population at very low frequencies. The Biomonitoring-based Approach 2 compares human biomonitoring data (as a measure of exposure) against biomonitoring guidance values that are consistent with available health-based exposure guidance values, such as biomonitoring equivalents (BEs), to identify substances with low concern for human health. The Rapid Screening for Substances with Limited General Exposure for Human Health is used to identify low concern substances by evaluating the potential for direct exposure from products and indirect exposure from environmental media.

Considering all the information presented in this draft screening assessment, it is proposed to conclude that the 34 substances in this assessment do not meet the criteria under paragraph 64(c) of CEPA as they are not entering the environment in a quantity or concentration or under conditions that constitute or may constitute a danger in Canada to human life or health.

It is therefore proposed to conclude that the 34 substances in this assessment do not meet any of the criteria set out in section 64 of CEPA.

Table of Contents

Synopsis	i
1. Introduction	1
2. Identity of substances	3
3. Sources and uses.....	3
4. Potential to cause ecological harm	7
5. Potential to cause harm to human health	8
5.1 Biomonitoring-based Approach 1.....	11
5.1.1 Hexanoic acid, 2-ethyl-, cerium(3+) salt	13
5.1.2 Germane, tetrachloro-	15
5.1.3 Lanthanum oxide, Lanthanum chloride and Lanthanum boride.....	17
5.1.4 Hexanoic acid, 2-ethyl-, neodymium (3+) salt	19
5.1.5 Praseodymium oxide.....	20
5.1.6 Tellurium oxide and Tellurium, tetrakis (diethylcarbamodithioato-S,S')...	22
5.1.7 Yttrium Oxide.....	24
5.2 Biomonitoring-based Approach 2.....	26
5.2.1 Bismuth-containing substances (7 CAS RNs)	27
5.2.2 Lithium-containing substances (16 CAS RNs).....	32
5.3 Rapid Screening of Substances with Limited General Population Exposure	38
6. Conclusion.....	39
References	40
Appendix A. List of substances, CAS RN numbers and assessment approaches	50
Appendix B. ERC-I classifications for the 34 substances addressed in this screening assessment.....	53
Appendix C. Median air and house dust concentrations of elements	55

List of Tables and Figures

Table 3-1. Summary of information on Canadian manufacturing and imports of 33 substances submitted through a CEPA section 71 surveys	3
Table 5-1. Whole blood concentrations of elements measured in biobank samples from the Canadian Health Measures Survey - Cycle 2 ^a	10
Table 5-2. Bismuth intake levels and average plasma concentrations in human volunteers based on Koch et al. (1996a) and Lacey et al. (1994).	31
Figure 5-1. Linear correlation between bismuth daily dose (mg/kg/day) and average plasma concentration (µg/L) in humans	31
Figure 5-2. Comparison of the median (bar) and the 95th percentile (whiskers) of the concentrations of whole blood lithium (µg/L) from the CHMS- cycle 2 (2009-2011) biobank with the biomonitoring equivalent of 10.4 (µg/L) for Health Canada's PDE value (indicated by a solid line).....	37

1. Introduction

Pursuant to section 74 of the *Canadian Environmental Protection Act, 1999* (CEPA) (Canada 1999), the Minister of the Environment and the Minister of Health have conducted a screening assessment of 34 substances to determine whether these substances present or may present a risk to the environment or to human health. The substances were identified as priorities for assessment as they met categorization criteria under subsection 73(1) of CEPA (ECCC, HC [modified 2017]).

The ecological risks of the 34 substances in this assessment were characterized using the Ecological Risk Classification of Inorganic Substances (ERC-I) (ECCC [modified 2018]), which is a risk-based approach that employs multiple metrics for both hazard and exposure, with weighted consideration of multiple lines of evidence for determining risk classification. Hazard characterization in ERC-I included a survey of published predicted no-effect concentrations (PNECs) and water quality guidelines, or the derivation of a new PNEC value when required. Exposure profiling considered two approaches: predictive modelling using a generic near-field exposure model for each substance and an analysis of measured concentrations collected by federal and provincial water quality monitoring programs using metal concentrations as a conservative indicator of exposure for individual substances. Modelled and measured predicted environmental concentrations (PECs) were compared to PNECs, and multiple statistical metrics were computed and compared to decision criteria to classify the potential for causing harm to the environment.

The human health risks of the substances in this assessment based on current levels of exposure, were characterized using one of three science approaches: Biomonitoring-based Approach 1 (Health Canada 2016a), Biomonitoring-based Approach 2 (Health Canada 2016b), or the Rapid Screening of Substances with Limited General Population Exposure (ECCC, HC [modified 2018]). Biomonitoring-based Approach 1 is a qualitative science approach used to identify substances with limited exposure based on substances or moieties measured in the Canadian population at very low frequencies. Biomonitoring-based Approach 2 compares human biomonitoring data (systemic exposure) against biomonitoring guidance values (based on available health-based guidance values), such as biomonitoring equivalents (BEs), to identify substances with low concern for human health. The Rapid Screening of Substances with Limited General Population Exposure for Human Health is used to identify low concern substances by evaluating the potential for direct exposure from products and, as needed, indirect exposure from environmental media.

Engineered nanomaterials (1 to 100 nm) that may be present in environmental media or products are not explicitly considered in this assessment, but measured concentrations of substances in the environment or human biomonitoring could include contributions from these sources. Similarly, this assessment does not explicitly consider ecological or health effects associated with nanomaterials.

This screening assessment proposes conclusions on 34 substances that were identified as having a low likelihood of causing harm to the environment and human health through these approaches.

This draft screening assessment was prepared by staff in the CEPA Risk Assessment Program at Health Canada and Environment and Climate Change Canada and incorporates input from other programs within these departments. The ERC-I Science Approach Document (SciAD) (ECCC [modified 2018]) was externally peer-reviewed and subject to a 60-day public comment period. External peer-review comments on the technical portions of the ERC-I SciAD were received from Dr. Peter Campbell (L'Institut national de la recherche scientifique, INRS), Mr. Geoff Granville (GCGranville Consulting Corp.), Dr. Carrie Rickwood (Natural Resources Canada), and Dr. Kevin Wilkinson (Université de Montréal). The Biomonitoring-based Approach 1 SciAD (Health Canada 2016a), the Biomonitoring-based Approach 2 SciAD (Health Canada 2016b), and the Rapid Screening of Substances with Limited General Population Exposure (ECCC, HC [modified 2018]) were each subject to a 60-day public comment period. Additionally, the Biomonitoring-based Approach 2 SciAD was externally peer-reviewed. External peer-review comments on the Biomonitoring-based approach 2 SciAD were received from Lynne Haber and Andrew Maier from Toxicology Excellence for Risk Assessment (TERA) and Judy LaKind from LaKind Associates. Public comments were received on the ERC-I SciAD and the Biomonitoring Approach 2 SciAD. While external comments were taken into consideration, the final content and outcome of the screening assessment remain the responsibility of Health Canada and Environment and Climate Change Canada.

This draft screening assessment focuses on information critical to determining whether substances meet the criteria as set out in section 64 of CEPA by examining scientific information and incorporating a weight of evidence approach and precaution.² The draft screening assessment presents the critical information and considerations on which the proposed conclusions are based.

² A determination of whether one or more of the criteria of section 64 of CEPA are met is based on an assessment of potential risks to the environment and/or to human health associated with exposures in the general environment. For humans, this includes, but is not limited to, exposures from ambient and indoor air, drinking water, foodstuffs, and products available to consumers. A conclusion under CEPA is not relevant to, nor does it preclude, an assessment against the hazard criteria specified in the *Hazardous Products Regulations*, which are part of the regulatory framework for the Workplace Hazardous Materials Information System for products intended for workplace use. Similarly, a conclusion based on the criteria contained in section 64 of CEPA does not preclude actions being taken under other sections of CEPA or other acts.

2. Identity of substances

The Chemical Abstracts Service Registry Numbers (CAS RN), *Domestic Substances List* (DSL) names, and common names for the 34 substances in this assessment are presented in Appendix A, Table A-1.

3. Sources and uses

Thirty-three of the 34 substances in this screening assessment were included in surveys issued pursuant to section 71 of CEPA (Canada 2009, 2012). Paraffin waxes and hydrocarbon waxes, oxidized, lithium salts (CAS RN 68649-48-9) was not surveyed. Table 3-1 presents a summary of the information reported on the total manufacture and total import quantities for these substances in Canada for the reporting years 2008 or 2011.

Table 3-1. Summary of information on Canadian manufacturing and imports of 33 substances submitted in response to CEPA section 71 surveys

DSL name	CAS RN	Total Manufacture ^a (kg)	Total Imports ^a (kg)	Survey data Reference ^b
Hexanoic acid, 2-ethyl-, cerium(3+) salt	56797-01-4	NR	100-1000	EC 2013
Germane, tetrachloro-	10038-98-9	10 000 – 100 000	NR	EC 2013
Lanthanum oxide (La ₂ O ₃)	1312-81-8	NR	100 000-1 000 000	EC 2013
Lanthanum chloride (LaCl ₃)	10099-58-8	NR	NR	EC 2013
Lanthanum boride (LaB ₆), (OC-6-11)-	12008-21-8	NR	NR	EC 2013
Hexanoic acid, 2-ethyl-, neodymium (3+) salt	73227-23-3	NR	1000-10 000	EC 2013
Praseodymium oxide (Pr ₂ O ₃)	12036-32-7	NR	100-1000	EC 2013
Tellurium oxide (TeO ₂)	7446-07-3	100 000-1 000 000	NR ^a	EC 2013
Tellurium, tetrakis (diethylcarbamo-dithioato-S,S')- (DD-8-111"1"1"1"1"1"1"-)	20941-65-5	NR	1 000 000-10 000 000	EC 2013
Yttrium oxide (Y ₂ O ₃)	1314-36-9	NR	10 000-100 000	EC 2013
Bismuth oxide (Bi ₂ O ₃)	1304-76-3	10 000 – 100 000	1000 – 10 000	EC 2013

Bismuth hydroxide nitrate oxide ($\text{Bi}_5(\text{OH})_9(\text{NO}_3)_4\text{O}$)	1304-85-4	NR	NR	EC 2013
Nitric acid, bismuth(3+) salt	10361-44-1	NR	NR	EC 2013
Bismuth vanadium oxide (BiVO_4)	14059-33-7	NR	20 500-130 000	EC 2009
Bismuth, tris(dimethylcarbamodithioato-S,S')- (OC-6-11)-	21260-46-8	NR	100 – 1000	EC 2013
Neodecanoic acid, bismuth(3+) salt	34364-26-6	NR	100 – 1000	EC 2013
Hexanoic acid, 2-ethyl-, bismuth(3+) salt	67874-71-9	NR	4 910	EC 2013
Acetic acid, lithium salt	546-89-4	NR	100-1000	EC 2013
Carbonic acid dilithium salt	554-13-2	14 361	100 000-1 000 000	EC 2013
Lithium hydroxide ($\text{Li}(\text{OH})$)	1310-65-2	NR	9 945	EC 2013
Octadecanoic acid, lithium salt	4485-12-5	NR	1000-10 000	EC 2013
Lithium	7439-93-2	NR	1000-10 000	EC 2013
Lithium chloride (LiCl)	7447-41-8	NR	10 000-100 000	EC 2013
Octadecanoic acid, 12-hydroxy-, monolithium salt	7620-77-1	10 000-100 000	100 000 – 1 000 000	EC 2013
Lithium fluoride(LiF)	7789-24-4	NR	6 300	EC 2013
Sulfuric acid, dilithium salt	10377-48-7	NR	1000-10 000	EC 2013
Silicic acid, lithium salt	12627-14-4	NR	36 060	EC 2013
Hypochlorous acid, lithium salt	13840-33-0	NR	16 000	EC 2013
Neodecanoic acid, lithium salt	27253-30-1	NR	1 615	EC 2013
Neodecanoic acid, dilithium salt	38900-29-7	NR	10 000-100 000	EC 2013
Silicic acid, lithium magnesium sodium salt	53320-86-8	NR	72 432	EC 2013
Fatty acids, C16-18, lithium salts	68783-37-9	10 000-100 000	NR	EC 2013
Bromic acid, sodium salt	7789-38-0	NR	1 000 - 20 000	EC 2009

Abbreviations: NR = Not reported above reporting threshold of 100 kg per reporting year

^a Values reflect quantities reported in response to CEPA section 71 surveys (Environment Canada 2009 and Environment Canada 2013). See surveys for specific inclusions and exclusions (schedules 2 and 3).

[illegible]

Consumer uses identified for bismuth-containing substances (7 CAS RNs) include medicinal or non-medicinal ingredients in licensed natural health products, medicinal ingredients in therapeutic drug products, an ingredient in cosmetics (as notified under the *Cosmetic Regulations*), sealants and solder flux. Certain bismuth-containing substances may also be used as components in the manufacture of food packaging materials (email from Food Directorate, Health Canada, to the ESRAB, Health Canada, dated March 09, 2018 unreferenced). Bismuth vanadium oxide may be used in plastics, rubber materials and in paint and coatings and hexanoic acid, 2-ethyl-, bismuth(3+) salt in adhesives and sealants.

Consumer uses identified for lithium-containing substances (16 CAS RNs) include use in water treatment, lubricants and greases, paper products, paints and coatings, sealants, batteries, water treatment (Environment Canada 2013), medicinal or non-medicinal ingredients in disinfectants, human or veterinary drug products, medicinal or non-medicinal ingredients in licensed natural health products, an ingredient in cosmetics (as notified under the *Cosmetic Regulations*), and active ingredient or formulant in registered pest control products (personal communication, email from the Pesticide Management Regulatory Agency, Health Canada to the ESRAB, Health Canada dated January 31, 2018; unreferenced). Certain lithium-containing substances may be used as components in the manufacture of food packaging materials and in incidental additives³ used in food processing establishments (personal communication, email from the Food Directorate, Health Canada, to the ESRAB, Health Canada, dated March 13, 2018; unreferenced). Lithium carbonate is used as a treatment for bipolar disorder (Kunasz 2006).

Sodium bromate was included in the Rapid Screening of Substances with Limited General Population Exposure. Sodium bromate was previously found in a small number of cosmetic products. It was previously described as a restricted ingredient on the List of Prohibited and Restricted Cosmetic Ingredients (more commonly referred to as the Cosmetic Ingredient Hotlist or simply the Hotlist), an administrative tool that Health Canada uses to communicate to manufacturers and others that certain substances may contravene the general prohibition found in section 16 of the *Food and Drugs Act* (F&DA), or may contravene one or more provisions of the *Cosmetic Regulations*. However, following a recent update to the Hotlist it is now described as a prohibited ingredient (Health Canada 2019). As sodium bromate is no longer permitted in cosmetics, there will no longer be potential for direct exposure to sodium bromate from cosmetic products. Sodium bromate may be used as a component in the manufacture of food packaging materials and in incidental additives used in food processing establishments (personal communication, email from the Food Directorate, Health Canada, to the ESRAB, Health Canada, dated September 28, 2017; unreferenced). No other consumer uses were identified for sodium bromate as it is a prohibited ingredient in cosmetics according to the Hotlist⁴ (Health Canada [modified 2019]).

³ While not defined under the *Food and Drugs Act* (F&DA), incidental additives may be regarded, for administrative purposes, as those substances which are used in food processing plants and which may potentially become adventitious residues in foods.

⁴ The List of Prohibited and Restricted Cosmetic Ingredients (more commonly referred to as the Cosmetic Ingredient Hotlist or simply the Hotlist), an administrative tool that Health Canada uses to communicate to manufacturers and others that certain substances may contravene the general prohibition found in section 16 of the *Food and Drugs Act* (FDA) or may contravene one or more provisions of the *Cosmetic Regulations*. Section 16 of the FDA states that "no person shall sell any cosmetic that has in or on it any substance that may cause injury to the health of the user." In

These substances have a wide array of industrial and commercial applications. According to non-confidential use information submitted in response to a CEPA section 71 survey, the substances in this group have various industrial uses such as paint additives, processing aids, catalysts, intermediates, viscosity adjusters, desiccants, pH adjusters, corrosion inhibitors, anti-scaling agents, adhesives and sealants, in paper products, batteries, plastics and rubber materials, industrial lubricants and greases, automotive, aircrafts and water treatments. Commercial uses in the metals sector has been reported for these 3 CAS RNs: tellurium oxide; carbonic acid, dilithium salt and lithium fluoride (Environment Canada 2013). Other uses identified in surveys issued pursuant to a CEPA section 71 notice beyond those identified here were notified as CBI.

4. Potential to cause ecological harm

4.1 Characterization of ecological risk

The ecological risks of the 34 substances in this assessment were characterized using the ERC-I (ECCC [modified 2018]), which is a risk-based approach that employs multiple metrics for both hazard and exposure, with weighted consideration of multiple lines of evidence for determining risk classification. A summary of the approach is outlined below; the approach is described in detail in the ERC-I science approach document (ECCC [modified 2018]).

Hazard characterization in ERC-I included a survey of published PNECs and water quality guidelines from domestic and international assessments. When no suitable existing PNEC or water quality guideline was found, hazard endpoint data were collected and, depending on data availability, either a species sensitivity distribution or an assessment factor approach was taken to derive a new PNEC value. In the case of the 34 substances in this assessment, hazard endpoint data were available from multiple sources including comprehensive literature searches for specific groups, targeted searches of the ECOTOX database (2016) and European Chemicals Agency (ECHA) registration dossiers (2016). In the absence of more recent information, the assumptions used in the 2006 categorization of the DSL were also considered (ECCC, HC [modified 2017b]).

addition, the Hotlist includes certain substances that may make it unlikely for a product to be classified as a cosmetic under the FDA (Health Canada [modified 2019]).

Exposure profiling in ERC-I considered two approaches: predictive modelling using a generic near-field exposure model and an analysis of measured concentrations of metals collected by federal and provincial water quality monitoring programs. The generic near-field exposure model used Canadian import and manufacture volumes and associated use information of the substances submitted in response to a CEPA section 71 survey (Environment Canada 2009; Environment Canada 2013). As an additional line of evidence, and to address substances where CEPA section 71 survey information was unavailable, trade merchandise import data were obtained for relevant harmonized system (HS) codes (CBSA 2016). Additionally, third-party market research reports were used to complement data from other sources and to fill information gaps for substances not included to date in a CEPA section 71 survey. Quantity data submitted in response to CEPA section 71 surveys, or obtained from the CBSA or market research were used in a conservative near-field exposure scenario similar to that used in previous rapid screening approaches (EC, HC 2013; EC, HC 2014; ECCC, HC 2016) and as further detailed in ECCC [modified 2018] to generate PECs.

In addition to using import, manufacture, and use information to model releases to the aquatic environment, reported release data were also available from the National Pollutant Release Inventory (NPRI) for certain substances or groups of substances. NPRI data for groups of substances (e.g., lithium carbonate) were conservatively considered applicable to the subsets of CAS RNs that are remaining priorities. A similar near-field risk-based evaluation was performed using NPRI reported release data for the last five years available at the time of preparation (2011 to 2015).

Water quality monitoring data for surface fresh waters were collected for each substance or metal moiety, where available, from multiple federal and provincial programs and repositories covering a number of ecoregions in Canada, as described in ECCC [modified 2018]. Measured concentrations were obtained for the period 2005 to 2015. For some metal moieties, measured concentrations in waterbodies exposed to metal mining activities and corresponding reference waterbodies were available from Environmental Effects Monitoring (EEM) studies conducted under the *Metals Mining Effluent Regulations* (MMER).

Modelled and measured PECs were compared to PNECs, and statistical metrics that consider both the frequency and magnitude of exceedances were computed and compared to decision criteria to classify the potential for ecological risk. Critical data and considerations used to create substance-specific ecological profiles and classifications associated with ecological risk, as well as identification of potential need for tracking of future use patterns, are presented in ECCC [modified 2018]. The 34 substances were classified as being of low ecological concern; classifications specific to these substances are presented in Table B-1 in Appendix B.

5. Potential to cause harm to human health

The human health risks of the substances in this assessment based on current levels of exposure, were characterized using one of three human health based approaches: the Biomonitoring-based Approach 1 (Health Canada 2016a), the Biomonitoring-based Approach 2 (Health Canada 2016b), or the Rapid Screening of Substances with Limited General Population Exposure approach (ECCC, HC [modified 2018]).

For the substances assessed with biomonitoring-based approaches in this document, whole blood concentrations generated from a recent Canadian Health Measures Survey (CHMS) biobank project (Jayawardene et al. 2021) were considered. The whole blood concentrations of these elements were not measured in the core CHMS. In this project, whole blood samples from the biobank of the CHMS cycle 2 were analysed at Health Canada's Health Products Laboratory in Longueuil, Quebec, to generate nationally representative population-level data (Health Canada 2013). The CHMS is a national survey carried out by Statistics Canada in partnership with Health Canada and the Public Health Agency of Canada, which collects information from Canadians about their general health (Health Canada [modified 2020a]). This survey is designed to be nationally representative and includes a biomonitoring component; metals were measured in whole blood and urine of approximately 5 000 to 7 000 Canadians per survey cycle. The CHMS is not a targeted survey, and thus does not target individuals with high metal exposure or living near point sources of exposure. The CHMS cycle 2 samples were collected from 2009 to 2011 in approximately 5752 Canadians aged 3 to 79, including pregnant women and both fasting and non-fasting individuals at 18 sites across Canada (Health Canada 2013).

The elemental concentrations in these CHMS samples were measured by Inductively Coupled Plasma Mass Spectrometry (ICP-MS). The methods used to detect these whole blood concentrations were sensitive, specific, accurate and reproducible. The LODs were considered to be sufficiently low to detect exposure in the Canadian population. When generating population-level whole blood concentrations, Statistics Canada estimated the 95% confidence intervals (CIs) for all means and percentiles by applying sample weights and bootstrap weights (Rao et al. 1992; Rust and Rao 1996). Sample weights took into account the complex survey design of the CHMS. Statistics Canada imputed values less than the limit of detection with values equivalent to half of the limits of detection (Jayawardene et al. 2021).

The biomonitoring data presented in Table 5.1 represent concentrations of elements in whole blood. These concentrations were used as surrogate exposure data for the specific substances (CAS RNs) that are being evaluated. There is very limited CAS RN specific exposure data, thus data on the total metal moiety was considered to be an acceptable surrogate as total metal moiety biomonitoring data include exposures from all bioavailable forms of the element. Biomonitoring data represent exposure from multiple sources. This includes indoor and outdoor air, soil, dust, water, food and/or potential exposures from products used frequently by consumers, such as some cosmetics and natural health products. Biomonitoring data also incorporate exposures from all routes (oral, dermal and inhalation). For each substance, relevant toxicokinetic

data were evaluated to determine whether the concentrations of elements in whole blood from available biomonitoring data were appropriate for assessing exposure. Several criteria have been established to understand the adequacy of the biomarker of exposure. According to Needham and Sexton (2000), the ideal biomarker should be sensitive, specific, biologically relevant, easy to collect, inexpensive to analyze, easily identified and persists in the body for long periods.

Table 5-1. Whole blood concentrations of elements measured in biobank samples from the Canadian Health Measures Survey - Cycle 2^a

Substance	LOD (µg/L)	Median (µg/L)	95 th percentile (µg/L)	Detection frequency (%) ^b	Human Health Approach used
Cerium	0.05	<0.05	<0.05	0.47	BM-1
Germanium	1	<1	<1	0	BM-1
Lanthanum	0.05	<0.05	<0.05	0.28	BM-1
Neodymium	0.05	<0.05	<0.05	0.12	BM-1
Praseodymium	0.02	<0.02	<0.02	0.09	BM-1
Tellurium	0.4	<0.4	<0.4	0	BM-1
Yttrium	0.06	<0.06	<0.06	0.12	BM-1
Bismuth	0.1	<0.1	<0.1	4.57	BM-2
Lithium	0.4	0.47	1.3	66.43	BM-2

Abbreviation: LOD = limit of detection; BM-1 = Biomonitoring-based Approach 1; BM-2 Biomonitoring-based Approach 2

^a Jayawardene et al. 2021.

^b Percentage of population with concentrations at or above the limit of detection

In the absence of CAS RNs specific inhalation exposure information, data on the metal moiety were used as surrogate inhalation exposure data for the specific substances (CAS RNs) in the assessment. Canadian air concentration data (24-hour particulate matter less than or equal to 2.5 [PM_{2.5}] air filter samples) for total bismuth and lithium are available from a study conducted in Windsor, Ontario, for indoor residential, outdoor residential and personal environments (Rasmussen 2017). In addition, total cerium and lanthanum were measured in outdoor air PM_{2.5} in 910 samples from 9 different sites across Canada as part of the National Air Pollution Surveillance (NAPS) Program (NAPS 2015). Indoor or personal air concentration data for cerium, germanium, lanthanum, neodymium, praseodymium, tellurium and yttrium have not been measured. However, a significant relationship between elemental concentrations in indoor particulate matter less than or equal to 10 (PM₁₀) and settled house dust has been demonstrated (Rasmussen et al. 2018). Nationally representative house dust data are available for all the elements included in this assessment (Rasmussen 2017; Rasmussen et al. 2017). Therefore, by using the elemental concentrations in settled-dust (Rasmussen et al. 2017), indoor air (PM₁₀) concentrations for cerium, germanium, lanthanum, neodymium, praseodymium, tellurium and yttrium were modelled (Rasmussen 2019). The measured median concentrations of elements in air PM_{2.5}

(ng/m³) and house dust (µg/g) are shown in Appendix C, Table C-1. The modelled indoor air concentrations (Rasmussen 2019) for cerium, germanium, lanthanum, neodymium, praseodymium, tellurium, and yttrium result in negligible inhalation exposure of the general population. Therefore, the risk to human health from inhalation exposure to these substances was not quantified in the current screening assessment.

5.1 Biomonitoring-based Approach 1

Substances characterized using the Biomonitoring-based Approach 1 are identified in Appendix A. This science approach is a qualitative biomonitoring-based approach that identifies substances of low concern for human health at the current levels of exposure which were identified as priorities for assessment as they met categorization criteria under subsection 73(1) of CEPA (Health Canada 2016a).

This biomonitoring-based approach considers available Canadian and U.S. biomonitoring data based on the analysis of the substance or moiety in whole blood, serum, and/or urine. Total concentrations of a substance (or moiety) in blood or urine may provide a biologically-relevant, integrated measure of exposures that may occur across multiple routes (e.g., oral, dermal and inhalation) and sources (including environmental media (e.g., soil, sediments, dust and water), diet, and frequent or daily use products). When biomonitoring data indicate that general population exposure is limited or unlikely, substances or moieties are considered to be of low concern with respect to human health. To determine if exposure is limited or unlikely, a number of metrics are taken into consideration. These metrics include the prevalence of exposure across the population (substances or moieties with limited biomarker⁵ detection frequency in the population are considered to have limited exposure), the magnitude of the biomarker concentration (if detected at the upper tails of the exposure distribution), the limit of detection (sufficiently low), the toxicokinetic properties of the substance or moiety, and the use pattern of the substance. The use pattern takes into consideration the sources and uses identified in section 3.

Toxicokinetic data for each substance were reviewed to ensure that the biomarkers measured in the biomonitoring study were adequate. The focus of the toxicokinetic data review was on the oral route of exposure as this would be the predominant route of potential intake for the general population. A literature search on toxicokinetic data available on each individual substance in the grouping was conducted. In the absence of kinetic data for the substance (CAS RN), the kinetic data from studies conducted on the metal moiety was used as a surrogate. The whole blood concentration of the

⁵ A biomarker of exposure is the chemical or its metabolite or the product of an interaction between a chemical and some target molecule or cell that is measured in a compartment in an organism (NRC 2006), e.g., a metal moiety measured in blood or urine.

substance can be considered as a suitable biomarker to quantify exposure from all routes and from all sources. Whole blood provides the concentration of bioavailable fraction of the substance at the target site of systemic health effects. Whole blood was preferred over plasma or serum as it contains all of the blood components (e.g., proteins, erythrocytes, platelets) and therefore there is a higher chance of detection regardless of the fraction of the blood into which the element partitioned. For population-level biomonitoring studies, such as the CHMS, it is reasonable to assume that the population distribution appropriately captures the variability in biomarker concentrations, even for substances with short elimination half-lives in blood.

For the substances captured in the Biomonitoring-based Approach 1 section of this assessment, the CHMS whole blood biomonitoring data indicate reasonably low long-term exposure in the general population of Canada. Therefore, in-depth reviews of systemic health effects from long-term exposure were not conducted for substances being evaluated by Biomonitoring-based Approach 1. However, carcinogenicity, mutagenicity and reproductive/developmental health effects associated with exposure to these substances were reviewed. In addition, a review of health effects from acute and short-term exposure (e.g., from substances with infrequent use) was conducted to identify whether substances are associated with adverse health effects following acute and short-term exposure scenarios.

Uncertainties of Biomonitoring-based Approach 1

Uncertainties associated with this approach have been outlined in the Biomonitoring-based Approach 1 SciAD (Health Canada 2016a). Additional sources of uncertainty include, but are not limited to: a lack of targeted data in CHMS, therefore the nationally representative biomonitoring data may not capture subpopulations with different exposures such as those living in the vicinity of industrial facilities or other point sources of exposure or a lack of biomonitoring data from young children under the age of 3 years; and the information on the sources of exposure to some of these substances in the general population. The CHMS cycle 2 biomonitoring data is representative of exposure during 2009 to 2011 in Canada. However, the use pattern analysis did not show any significant change in sources and uses for the substances included in this assessment from the time the CHMS survey was conducted to the present. Thus, it is likely that the biomonitoring data represent current levels of exposure, but do not capture exposures from potential future uses.

In the absence of substance specific kinetic, health effects and exposure data, data available on the metal moiety was used as a surrogate. It is important to note that there may be different bioavailability and health effects associated with specific substances versus the metal moiety, in particular with soluble and insoluble substances.

Despite the above-noted uncertainties, the confidence in the assessment of substances containing cerium, germanium, lanthanum, neodymium, praseodymium, tellurium and

yttrium in this assessment conducted using Biomonitoring-based Approach 1 is considered to be high.

It was determined that the Biomonitoring-based Approach 1 was appropriate for risk characterization for 10 substances.

5.1.1 Hexanoic acid, 2-ethyl-, cerium(3+) salt

There is no toxicokinetic data or human health effects data available on hexanoic acid, 2-ethyl-, cerium(3+) salt. Therefore, available data on substances that contain the cerium metal moiety were used as a surrogate. Based on the results of the literature search, it was determined that toxicokinetic studies for cerium-containing substances are conducted primarily using cerium chloride.

Toxicokinetic data

Cerium is poorly absorbed by the gastrointestinal (GI) tract. Bouchard et al. (2017) conducted a kinetic study on rare earth metals using male Sprague-Dawley rats. The study was conducted in compliance with the OECD Test Guideline 417. Male rats orally exposed to cerium chloride at 100 or 1000 mg/kg bw/day (n=5/dose) absorbed 0.4% and 0.1% of the administered dose, respectively (Bouchard et al. 2017). Similarly, Moskalev (1959) reported 0.03% absorption by the GI tract 3 days after oral administration of cerium chloride to rats. Other authors have reported age-dependent variation in the absorption of radioactive cerium (Kostial et al. 1989; Inaba and Lengemann 1972, as cited in US EPA (2009a). Adult rats orally exposed to radioactive cerium salts showed less than 1% absorption (Kostial et al. 1989; Inaba and Lengemann 1972; Shiraishi and Ichikawa 1972 as cited in US EPA 2009a). US EPA (2009a) concluded that a very small fraction of ingested cerium is absorbed by the GI tract.

Once absorbed, cerium is distributed to the blood. The highest average percentage of the administered dose recovered from the blood was 0.025% within 0.5 to 1 hours post administration in experimental animals (Bouchard et al. 2017). Once absorbed, radioactive cerium is primarily retained in the bone, followed by the liver, muscle, kidney and ileum. Body burdens at forty days after oral administration were 87%, 4.1%, 2.0%, 1.1% and 0.26% of the retained dose, respectively in bone, liver, muscle, kidney and ileum (Shiraishi and Ichikawa 1972).

Cerium is rapidly cleared from the blood, with an average half-life of 3 hours in rats (Bouchard et al. 2017). The primary route of elimination for cerium is the feces (US EPA 2009a). Bouchard et al. (2017) reported that approximately 90% to 100% of orally administered cerium is eliminated in feces during 0 to 72 hours post-dosing. Urine is a minor route of elimination. The maximum percentage of orally administered dose recovered in urine is about 0.78% (Bouchard et al. 2017). Other authors have reported a similar elimination pattern; Moskalev (1959) reported fecal excretion of 99% of orally

administered radio-labelled cerium within 3-days post-administration. Bjondahl (1976) reported urinary elimination of less than 1% of intravenous (i.v.) injected cerium chloride over 4 days in mice. A relatively short elimination half-life suggests there is low systemic exposure to cerium (US EPA 2009a).

Human inhalation data from occupational studies indicated that, in general, inhaled cerium (as cerium oxide) is not systemically available (Yokel et al. 2014). Based on kinetic data from animal studies and human occupational studies, it can be expected that systemic exposure to cerium in the general population is low (US EPA 2009a).

Biomonitoring data

A summary of the biomonitoring data for total cerium in whole blood is provided in Table 5-1 and are used as surrogate exposure data for this specific cerium-containing substance. Cerium was not detected in 99.53% of the Canadian population at the limit of detection of 0.05 µg/L (50 ng/L). The LOD was considered to be sufficiently low. The median and 95th percentile cerium concentrations were below the detection limit.

Human health effects

The toxicology of cerium-containing substances was reviewed by US EPA (2009a). While acute oral toxicity data for cerium-containing substances is limited, oral gavage studies, in which rodents were exposed up to 1000 mg/kg bw as cerium chloride-sodium citrate complex, showed GI tract irritation and hyperactive lymphoid follicles (US EPA 2009a). Limited available sub-chronic and chronic toxicity studies in animals have reported effects in the cardiovascular system, including cardiac fibrosis and changes in hemoglobin oxygen affinity. However, these studies are limited by poor study designs (US EPA 2009a). There are insufficient data to conclude on carcinogenicity, genotoxicity, reproductive and developmental effects for cerium-containing substances (US EPA 2009a). Based on kinetic data and the available toxicity data, acute and sub-chronic (or short-term) exposure to hexanoic acid, 2-ethyl-, cerium(3⁺) salt is not likely to cause adverse health effects in humans.

Risk Characterization

The available information on this substance, i.e., low detection of total cerium in biomonitoring data (whole blood), the low absorption as indicated in the toxicokinetic data, and limited substance-specific consumer uses ([CBI], including infrequent use products), indicates that exposure is minimal for hexanoic acid, 2-ethyl- cerium (3⁺) salt in the general population. Thus, hexanoic acid 2-ethyl- cerium (3⁺) salt in this assessment is of low concern to the health of the general public in Canada at current levels of exposure.

5.1.2 Germane, tetrachloro-

There is no toxicokinetic data and limited human health effects data available on germane, tetrachloro-. Therefore, available data on substances that contain the germanium metal moiety were used as a surrogate. Based on the results of the literature search, it was determined that toxicokinetic studies for germanium-containing substances are conducted primarily using germanium dioxide.

Toxicokinetic data

Germanium was almost completely and rapidly absorbed after oral exposure in rats (10 mg of germanium dioxide by oral gavage), amounting to 76.3% of the administered dose within 4 hours and 96.4% in 8 hours (Rosenfeld 1954; Browning 1969; Ohri et al. 1993). Human patients that were treated with 25 to 75 mg/kg bw of radio-labelled germanium (Ge^{132}) absorbed 30% of the administered dose from the GI tract (Miyao et al. 1980).

Once absorbed, germanium is rapidly transported in blood to other tissues and organs throughout the body without binding to plasma proteins (Dudley and Wallace 1952). When rats were orally administered germanium dioxide (6 $\mu\text{mol/kg}$ bw/day), the highest initial concentrations of germanium were found in kidney and liver, but these concentrations declined as early as 6 hours after absorption (Browning 1969; Kobayashi and Ogra 2009). No selective tissue localization or storage was detected in animals tested (Dudley and Wallace 1952). Twenty-four hours after mice were orally exposed to germanium dioxide, there were no detections of germanium in any of the tissues, which suggest rapid elimination of germanium from the body (Shinogi et al. 1989). The biological half-lives of germanium in the blood, brain and pancreas of mice were 1.2, 6.3 and 4.5 hours, respectively (Shinogi et al. 1989). In rats, half-lives were 1.5 days for whole body retention, 1 to 2 days in the liver and 4 days in kidneys (Rosenfeld 1954). Available data for other species (e.g., rabbit) are indicative of a half-life closer to 72 hrs (Dudley and Wallace 1952).

Absorbed germanium excretes primarily via urine followed by feces without being metabolized (Dudley and Wallace 1952; Rosenfeld 1954; Browning 1969; Kobayashi and Ogra 2009). Dudley and Wallace (1952) and Dudley (1953) showed that when radio-labelled germanium dioxide was intravenously injected to dogs and rabbits, 90% and 75% of administered germanium, respectively, was excreted in urine within 72 hours. In both species, an average of 9% was excreted in the feces during that time. When human volunteers were given a single oral dose of 100 mg Ge-132 , urinary excretion peaked at around 3 hours and the concentration in urine returned to pre-dosing levels after 24 hours (Tao and Bolger 1997). The inhalation elimination half-life of germanium (exposed as germanium or germanium dioxide) in occupationally exposed workers ranged from 8.2 to 18.1 hours (Roels and Buchet 2001).

Biomonitoring data

A summary of the biomonitoring data for total germanium in whole blood is provided in Table 5-1 and are used as surrogate exposure data for this specific germanium-containing substance. Germanium was not detected in 100% of the Canadian population at the limit of detection of 1 µg/L (1 000 ng/L). The LOD was considered to be sufficiently low. The median and 95th percentile germanium concentrations were below the detection limit.

Human health effects

Acute toxicity of germanium is minimal with LD₅₀ values ranging from approximately 6 to 13 g radioactive germanium/kg bw in male and female mice (Tao and Bolger 1997). Animal sub-chronic and chronic dietary and drinking water studies have reported that the kidney is the primary target organ for germanium toxicity (Tao and Bolger 1997). In a sub-chronic study, when rats were fed 150 mg/kg bw/day of germanium dioxide for 13 weeks, animals showed biochemical and pathological changes associated with renal toxicity, including increased blood urea nitrogen, serum creatinine and renal cell degeneration (Tao and Bolger 1997). Based on the results of chronic studies (Tao and Bolger 1997), it is evident that germanium-containing substances are more harmful to health when administered via drinking water than in the diet.

Tao and Bolger (1997) report human cases linking prolonged intake (2 to 22 months) of germanium products (e.g., germanium-containing dietary supplements) with renal failure. Impaired renal function was observed long after germanium intake ceased (Tao and Bolger 1997). According to the available literature, germanium in the form of germanium dioxide is more harmful to humans than to rodents (Tao and Bolger 1997). However, the available toxicity data are predominantly for germanium dioxide, which is not a substance included in this grouping and lower toxicity has been observed for other germanium substances (Browning 1969). In addition, the purity or the composition of germanium compounds used in these human case studies and animal studies were not well documented. There are no indications of carcinogenicity, genotoxicity, reproductive and developmental effects for germanium-containing substances (Tao and Bolger 1997). Furthermore, due to rapid elimination from the body and lack of storage sites, germanium is not expected to be systemically available in humans.

Risk characterization

On the basis of the available information on this substance, i.e., no detection of total germanium in biomonitoring data (whole blood) and no CAS RN specific consumer uses (including infrequent use products identified), exposure is minimal for germane, tetrachloro- in the general population. Thus, germane, tetrachloro- in this assessment is of low concern to the health of the general population of Canada at current levels of exposure.

5.1.3 Lanthanum oxide, Lanthanum chloride and Lanthanum boride

Toxicokinetic data

There is limited toxicokinetic data or human health effects data available on lanthanum oxide, lanthanum chloride or lanthanum boride. Therefore, available data on substances that contain the lanthanum metal moiety were used as a surrogate. Based on the results of the literature search, oral toxicokinetic studies for lanthanum were primarily conducted using lanthanum carbonate, which is used to prevent phosphate absorption in patients with hyperphosphataemia due to renal failure (Pennick et al. 2006; Mohammed and Hutchison 2009; Shire Pharmaceutical 2012). Lanthanum carbonate is insoluble in water; however it is soluble in the acidic environment of the upper gastrointestinal tract to produce free lanthanum cations (Curran and Robinson 2009).

GI tract absorption of lanthanum from orally administered lanthanum carbonate in humans is low, ranging from 0.00015% to 0.00224% (averaging about 0.001%) (Pennick et al. 2006). A similar result was reported in a dog study, in which oral absorption was reported as 0.00005% for both sexes (Shire Pharmaceutical 2002 as cited in US FDA 2004). The International Commission on Radiological Protection (ICRP) (Publication 30) recommended a reference GI absorption fraction of 3×10^{-4} for all forms of lanthanum and all lanthanoids (ICRP 1981). The primary reason for low oral absorption of lanthanum carbonate is due to the formation of chelate complexes with dietary phosphates in the gastrointestinal tract (Damment and Pennick 2008).

Plasma concentrations of lanthanum in dialysis patients receiving therapeutic doses (up to 3 g/day lanthanum carbonate for up to 4 weeks) are reported to be low (about 0.2 to 0.78 µg/L) (Pennick et al. 2006). In systemic circulation, almost all lanthanum is protein-bound (>99.7% in humans) and binding is non-specific (Shire Pharmaceutical 2012). Kinetic studies indicate that there is no significant binding of lanthanum to red blood cells (Damment and Pennick 2007). Lanthanum plasma concentrations decline either biphasically or triphasically, with a mean terminal elimination half-life of 35 hours (range 16-48 hours) (Marroum and Dorantes 2004; Pennick et al. 2006).

Lanthanum predominantly deposits in bones and liver (Pennick et al. 2006). Deposition of less than 1 µg lanthanum/g tissue has been demonstrated in long-term animal studies, in which animals were exposed to oral doses of greater than 50 g lanthanum/day (Shire Pharmaceutical 2012). Lanthanum deposited in bones eliminates slowly, with biological half-lives more than 1000 days (ICRP 1981, 1994).

Fecal elimination is the primary route of elimination for both unabsorbed and biliary excreted lanthanum, which amounts to approximately 93.4% of the administered dose (Pennick et al. 2006; Damment and Pennick 2008; Shire Pharmaceutical 2012). Approximately 1.7% of plasma clearance occurs through the renal system in humans (Pennick et al. 2006).

Biomonitoring data

A summary of the biomonitoring data for total lanthanum in whole blood is provided in Table 5-1 and are used as surrogate exposure data for these specific lanthanum-containing substances. Lanthanum was not detected in 99.72% of the Canadian population at the limit of detection of 0.05 µg/L (50 ng/L). The LOD was considered to be sufficiently low. The median and 95th percentile lanthanum concentrations were below the detection limit.

Human health effects

Lanthanum substances have been reviewed by the US EPA (2018) and a REACH dossier is available (REACH 2018a; b). On the basis of an unpublished developmental neurotoxicity study in rats conducted according to OECD Test Guideline 426, maternal rats were exposed up to 1214 mg lanthanum/kg bw/day as lanthanum carbonate from implantation (gestational day 6) throughout lactation (post-natal day 20) (REACH 2018a). It was reported that there is no convincing evidence for a possible neurotoxic or developmental neurotoxic effect of lanthanum chloride in experimental animals (REACH 2018b).

In comparison, some studies indicated developmental neurotoxicity effects of lanthanum substances at low doses of exposure in experimental animals (Feng et al. 2006a; Behets et al. 2006a; Feng et al. 2006b; He et al. 2008) to lanthanum carbonate as an analogue for lanthanum chloride. In 2018, the US EPA identified a LOAEL for chronic exposure of experimental animals to lanthanum chloride as low as 1 mg lanthanum/kg bw/day based on neurological effects reported in He et al. (2008). While observations of developmental neurotoxicity could indicate a high hazard potential, to date there are no international classifications for reproductive toxicity for the lanthanum substances in this assessment.

No carcinogenic data were identified for soluble lanthanum (US EPA 2018).

Risk characterization

There were no reports of manufacture, import or uses identified in the survey issued pursuant to section 71 of CEPA for lanthanum boride and lanthanum chloride. There were no reports of manufacture for lanthanum oxide and imports were limited to industrial uses as a catalyst. Exposure from environmental media is expected to be negligible. Consumer uses identified were very limited (i.e., swimming pool use for lanthanum chloride) and were not expected to result in significant exposure.

On the basis of the available information on this substance, i.e., low detection of total lanthanum in biomonitoring data (whole blood), the low absorption as indicated in the toxicokinetic data, and limited CAS RN specific consumer uses, exposure is minimal for lanthanum oxide, lanthanum chloride, and lanthanum boride in the general population.

Thus, lanthanum oxide, lanthanum chloride, and lanthanum boride in this assessment are of low concern to the health of the general population of Canada at current levels of exposure. However, as noted above, the possible developmental neurotoxicity attributed to lanthanum chloride has not been fully evaluated within this assessment or internationally.

5.1.4 Hexanoic acid, 2-ethyl-, neodymium (3+) salt

There is no toxicokinetic data or human health effects data available on hexanoic acid, 2-ethyl-, neodymium (3+) salt. Therefore, available data on substances that contain the neodymium metal moiety were used as a surrogate. Based on the results of the literature search, it was determined that toxicokinetic and human health effects studies for neodymium-containing substances are conducted primarily using neodymium chloride.

Toxicokinetic data

Neodymium is poorly absorbed from the GI tract in both humans and experimental animals (US EPA 2009b). Bouchard et al. (2017) showed that male rats exposed to neodymium (as neodymium chloride) at 100 or 1000 mg/kg bw/day through oral gavage absorb approximately 0.6% and 0.07% of the administered dose, respectively. Pawel et al. (2007) reported oral absorption in the range of 0.01% to 0.1% based on human and animal data.

Once absorbed, neodymium showed rapid blood clearance, with an elimination half-life of, on average, 3 hours in rats (Bouchard et al. 2017). The ICRP kinetic model for humans applied a blood half-life of 0.25 day (6 hours) (ICRP 1981, 1994).

From blood, neodymium distributes to tissues. The highest concentrations of neodymium were found in the liver (37% of the absorbed dose), followed by the spleen, kidney and lungs (in decreasing order) after i.v. administration of 1 mg/kg of neodymium chloride (Bouchard et al. 2017). According to the ICRP model, approximately 45% of absorbed neodymium is distributed to liver, 45% to bone, and 10% to excretion pathways, such as the kidney and lungs (ICRP 1981, 1994). The ICRP kinetic model suggests that the liver is an important organ for neodymium accumulation. The ICRP model assigned the following elimination half-lives: 5 years for liver and other excretion pathways (such as kidney and lungs); 20 years for cortical bone surfaces; and 5 years for trabecular bone surfaces (ICRP 1981, 1994).

Bouchard et al. (2017) showed that approximately 100% and 53% of neodymium from an i.v. administered dose was recovered in feces during the 0-72 hours post dosing of rats with 100 or 1000 mg neodymium chloride/kg bw/day, respectively. According to this study, the urinary elimination is very low, with a maximum urinary elimination of 0.78% of an orally administered dose during 0 – 72 hour post dosing period. Conversely, the

ICRP model has assigned an equal excretion dose from the urinary or fecal route (i.e., an elimination ratio of 1:1) from systemic activity (ICRP 1994).

Biomonitoring data

A summary of the biomonitoring data for total neodymium in whole blood is provided in Table 5-1 and are used as surrogate exposure data for this specific neodymium-containing substance. Neodymium was not detected in 99.88% of the Canadian population at the limit of detection of 0.05 µg/L (50 ng/L). The LOD was considered to be sufficiently low. The median and 95th percentile neodymium concentrations were below the detection limit.

Human health effects

US EPA (2009b) has published an assessment report that derived Provisional Peer-Reviewed Toxicity Values for neodymium chloride. The oral LD₅₀ values for rats and mice were 905 and 3024 mg neodymium/kg bw/day, respectively (US EPA 2009b). In a 90-day dietary study, male and female rats were administered neodymium chloride. The NOAEL was identified as the highest dose tested (i.e., 840 and 950 mg neodymium chloride/kg bw/day, respectively for males and females) (Haley et al. 1964 as cited in US EPA 2009b). There are no indications of carcinogenicity, genotoxicity, reproductive and developmental effects for neodymium (US EPA 2009b).

Based on available kinetic data and limited toxicity data, acute and sub-chronic (short-term) exposure to hexanoic acid, 2-ethyl-, neodymium (3+) salt is not likely to cause adverse health effects in humans.

Risk characterization

On the basis of the available information on this substance, i.e., low detection of total neodymium in biomonitoring data (whole blood), the low absorption as indicated in the toxicokinetic data, and limited CAS RN specific consumer uses (CBI), exposure is minimal for hexanoic acid, 2-ethyl-, neodymium (3+) salt. Thus, hexanoic acid, 2-ethyl-, neodymium (3+) salt in this assessment is of low concern to the health of the general population of Canada at current levels of exposure.

5.1.5 Praseodymium oxide

There is limited toxicokinetic data and human health effects data available on praseodymium oxide. Therefore, available data on substances that contain the praseodymium metal moiety were used as a surrogate. Based on the results of the literature search, it was determined that human health effects studies for praseodymium-containing substances are conducted primarily using praseodymium chloride.

Toxicokinetic data

Praseodymium is poorly absorbed from the GI tract. Bouchard et al. (2017) showed that when male rats were exposed to (as praseodymium oxide) at 100 or 1000 mg/kg bw/day through oral gavage, the respective absorption was approximately 1.8% and 0.9% of the administered dose. Pawel et al. (2007) reported oral absorption in the range of 0.01% to 0.1% based on animal data.

The intravenous data from the same study showed that praseodymium was rapidly cleared from blood, with an average half-life of 3 hours in rats (Bouchard et al. 2017). From blood, praseodymium is distributed throughout the body, with the highest accumulation in liver, followed by the spleen, kidney and lungs during 7 days post dosing (Bouchard et al. 2017).

Approximately 90% and 100% of praseodymium from the orally administered dose of 100 and 1000 mg praseodymium oxide/kg bw, respectively were recovered in feces within 72 hours post dosing, whereas a very small fraction (approximately 0.02% for both dose levels) was eliminated in urine (Bouchard et al. 2017).

Biomonitoring data

A summary of the biomonitoring data for total praseodymium in whole blood is provided in Table 5-1 and are used as surrogate exposure data for this specific praseodymium-containing substance. Praseodymium was not detected in 99.91% of the Canadian population at the limit of detection of 0.02 µg/L (20 ng/L). The LOD was considered to be sufficiently low. The median and 95th percentile praseodymium concentrations were below the detection limit.

Human health effects

US EPA (2009c) has published an assessment report that derived Provisional Peer-Reviewed Toxicity Values for praseodymium chloride. The LD₅₀ for rats and mice were 1134 and 2565 mg praseodymium/kg bw, respectively (US EPA 2009c). A REACH dossier available on praseodymium oxide reported an LD₅₀ of >2 000 mg/kg bw in rats from an unnamed study (OECD 401) (REACH 2018a). In rats exposed to praseodymium chloride through their diet for 90 days, no treatment related effects were reported. The highest doses tested in male and female rats, which were 479 and 541 mg praseodymium/kg bw/day, respectively were considered as NOAELs (Haley et al. 1964 as cited in US EPA 2009c). There are no indications of carcinogenicity, genotoxicity, reproductive and developmental effects for praseodymium (US EPA 2009c).

Based on available kinetic and toxicity data, acute and sub-chronic (short-term) exposure to praseodymium oxide is not likely to cause adverse health effects in humans.

Risk characterization

The available information on this substance, i.e., low detection of total praseodymium in biomonitoring data (whole blood), the low absorption as indicated in the toxicokinetic data, and no CAS RN specific consumer uses (including infrequent use products identified) data presented above, confirms that exposure is minimal to praseodymium oxide. Thus, praseodymium oxide in this assessment is of low concern to the health of the general population of Canada at current levels of exposure.

5.1.6 Tellurium oxide and Tellurium, tetrakis (diethylcarbamodithioato-S,S')

There is limited toxicokinetic data available on tellurium oxide and tellurium, tetrakis (diethylcarbamodithioato-S,S'). Therefore, available data on substances that contain the tellurium metal moiety were used as a surrogate. Based on the results of the literature search, it was determined that toxicokinetic studies for substances containing the tellurium metal moiety are conducted primarily using sodium tellurite.

Toxicokinetic data

The fraction of tellurium orally absorbed depends on its valence state. Based on volunteer studies, the estimated oral absorption of tellurate (Na_2TeO_4), tellurite (Na_2TeO_3) or metallic tellurium was 23%, 21% and 10%, respectively (Kron et al. 1991a). A study reported dermal absorption of about 5% within 15 minutes after application of an unknown quantity of radioactive tellurium to the skin of piglets (MAK 2006).

Tellurium is transferred throughout the body via systemic circulation. In blood, approximately 90% of tellurium is found in erythrocytes in both humans and rats (Agnew and Cheng 1971; Kron et al. 1991b). The highest tissue tellurium levels were found in the kidneys followed by heart, lung, spleen and liver. Bones act as a long-term storage, containing 90% of total tellurium body burden (Schroeder et al. 1967). Studies have shown that tellurium can transfer to the fetus through the placenta, and can also cross the blood brain barrier (Agnew et al. 1968; Agnew 1972). Based on tellurium retention half-lives, the tissues could be divided into three groups: lungs, blood, liver and heart with a half-life of approximately 10 days; muscle, spleen, and kidneys with a half-life of approximately 20 days; and femur (skeleton) with a half-life greater than 200 days (Hollins 1969).

The main metabolic pathway for tellurium is through methylation. Trimethyl tellurium is a major urinary metabolite of tellurium (Ogra et al. 2007; Kobayashi and Ogra 2009).

Elimination is mainly dependent on the chemical form and route of exposure to tellurium. In rats, 79% of the orally administered radio-labelled tellurium dioxide (^{127}Te as tellurium dioxide) was found in the feces and 3% in the urine (MAK 2006). Kron et al. (1991a) showed that healthy volunteers (n=5) orally exposed to tellurite, tellurate,

metallic form and bound forms in cress salad (cress was cultivated in tellurium-containing water), excreted <8%, 3% to 25%, 4% to 9% and 3% in the urine, respectively. Small amounts (0.1%) of absorbed tellurium are eliminated via exhaled air as dimethyl telluride, which causes garlic-like breath odour (Gerhardsson 2015; HSDB 2009). Orally administered radio-labelled tellurium as tellurium dioxide showed a multi-phasic elimination pattern in rats: 84% was eliminated during the first phase ($t_{1/2} = 3$ hours), 11% in a second phase ($t_{1/2} = 19$ hours) and 5% in a third phase ($t_{1/2} = 12.3$ days) (MAK 2006).

After a single intra-tracheal installation of cadmium telluride in rats, the tellurium content in the lungs decreased to 75% after 3 days, 69% after 7 days, 53% after 14 days, and 33% after 28 days. One day after installation, tellurium was detected in the spleen, kidneys, femur, liver and blood, with maximum levels reached after 14 days (MAK 2006).

Biomonitoring data

A summary of the biomonitoring data for total tellurium in whole blood is provided in Table 5-1 and are used as surrogate exposure data for these specific tellurium-containing substances. Tellurium was not detected in 100% of the Canadian population at the limit of detection of 0.4 µg/L (400 ng/L). The LOD was considered to be sufficiently low. The median and 95th percentile tellurium concentrations were below the detection limit.

Human health effects

RIVM (1998) reviewed tellurium toxicity in either laboratory animals or humans. In addition, REACH dossiers is available for tellurium dioxide and tellurium, tetrakis (diethylcarbamodithioato-S,S') (REACH 2018c). Acute toxicity of tellurium dioxide and tellurium, tetrakis (diethylcarbamodithioato-S,S') via the oral route is very low; the LD₅₀ values in rats are >5000 mg/kg bw for both tellurium dioxide and tellurium, tetrakis (diethylcarbamodithioato-S,S') (REACH 2018c; REACH 2020). When volunteers were given a single oral dose up to 40 g (570 mg tellurium/kg bw/day) metallic tellurium, no toxic symptoms were observed (RIVM 1998; REACH2017a). A short-term combined repeated dose toxicity study with the reproduction/developmental toxicity screening test (OECD 422) was conducted in rats administered tellurium diethyldithiocarbamate (i.e. tellurium, tetrakis (diethylcarbamodithioato-S,S') via oral gavage. No adverse effects were reported at the highest dose tested (NOAEL=1 mg tellurium diethyldithiocarbamate/kg bw/day) (REACH 2018c). Same study reported a NOAEL of 5 mg tellurium diethyldithiocarbamate/kg bw/day for reproductive toxicity (REACH 2018c). In addition, a 28-day repeated dose study (OECD 407) that administered tellurium dioxide to rats via oral gavage reported a LOAEL of 25 mg tellurium dioxide/kg bw/day for male rats based on a significant decrease in body weight (21%), whereas female rats did not show any effects at the same dose (REACH 2020). A 2-year carcinogenicity studies conducted in rats and mice administered ethyl telluric [i.e.

tellurium, tetrakis (diethylcarbamodithioato-S,S') in diet suggested no evidence of carcinogenicity (NTP 1979). In addition, there is no evidence to indicate that tellurium, tetrakis (diethylcarbamodithioato-S,S') is genotoxic (Valencia et al. 1985; Mortelmans et al. 1986). Based on available kinetic and toxicity data, acute and sub-chronic (short-term or infrequent) exposure to tellurium oxide and tellurium, tetrakis (diethylcarbamodithioato-S,S') are not likely to cause adverse health effects in humans.

Risk characterization

On the basis of the available information on this substance, i.e., no detection of total tellurium in biomonitoring data (whole blood), toxicokinetic data and no substance (CAS RN)-specific consumer uses identified (including infrequent use products), exposure to tellurium oxide and tellurium, tetrakis (diethylcarbamodithioato-S,S') is minimal. Thus, tellurium oxide and tellurium, tetrakis (diethylcarbamodithioato-S,S') in this assessment are of low concern to the health of the general population of Canada at current levels of exposure.

5.1.7 Yttrium Oxide

There is no toxicokinetic data available on yttrium oxide. Therefore, available data on substances that contain the yttrium metal moiety were used as a surrogate. Based on the results of the literature search, it was determined that toxicokinetic studies for substances containing the yttrium metal moiety are conducted primarily using yttrium chloride.

Toxicokinetic data

Bouchard et al. (2017) showed that the respective GI absorption of male rats exposed to yttrium chloride at 100 or 1000 mg/kg bw/day through oral gavage was approximately 6% and 23% of the administered dose.

Hirano et al. (1993) showed that when male rats were each given 1 mg (4 mg yttrium/kg bw) of yttrium chloride via i.v. injection, the blood yttrium levels decreased rapidly within 3 hours. Authors also noted approximately 75% of the dose was accumulated in the liver, with an elimination half-life of 144 days. According to the study authors, the long half-life in liver was likely due to insolubilized yttrium in lysosomal inclusions (Hirano et al. 1993). The highest concentrations of yttrium were found in liver followed by the spleen, femur and then kidneys on day 8 following i.v. injection of yttrium at 10 mg/kg bw (Nakamura et al. 1993).

When Nakamura et al. (1991) orally administered male rats with yttrium chloride at 100 and 1000 mg/kg bw, approximately 97% and 94%, respectively, were recovered in feces. Bouchard et al. (2017) estimated fecal elimination of yttrium for the same dose levels of yttrium chloride as 88% and 68%, respectively. Urine is a minor route of elimination. Urine elimination of orally administered yttrium chloride was less than 1%

(Hayashi et al. 2006; Kitamura et al. 2012; Bouchard et al. 2017). Conversely, Nakamura et al. (1991) did not detect yttrium in urine or any other tissues.

Intra-tracheal instillation of yttrium chloride in rats indicated slow pulmonary clearance, with a half-life of 168 days (Hirano et al. 1990). Wenzel et al. (1969) documented systemic distribution of yttrium after inhalation exposure to a radio-labelled yttrium isotope. The highest levels were reported in skeleton, followed by lungs and liver (Wenzel et al. 1969).

Biomonitoring data

A summary of the biomonitoring data for total yttrium in whole blood is provided in Table 5-1 and are used as surrogate exposure data for this specific yttrium-containing substance. Yttrium was not detected in 99.88% of the Canadian population at the limit of detection of 0.06 µg/L (60 ng/L). The LOD was considered to be sufficiently low. The median and 95th percentile yttrium concentrations were below the detection limit.

Human health effects

There are no indications of carcinogenicity, genotoxicity, reproductive and developmental effects for yttrium oxide (REACH 2017b). The results of micronucleus and comet assays in rats concluded that yttrium oxide is not genotoxic (Panyala et al. 2017; Panyala et al. 2019). The LD₅₀ value in rats via oral gavage is >5000 mg yttrium oxide/kg bw (REACH 2017b). Lambert et al. (1993) reported an acute oral LD₅₀ greater than 5.0 g yttrium oxide/kg in rats. A more recent acute oral toxicity study in rats (OECD 420) reported no adverse effects at 1000 mg yttrium oxide/kg bw/day (highest dose tested) (Panyala et al. 2017). A combined repeated dose toxicity study with a reproduction/developmental toxicity screen (OECD 422) in rats exposed via oral gavage for at least 28 days for males and 54 days for females did not report any effects up to the maximum dose tested (i.e., 1000 mg yttrium oxide/kg bw/day, a NOAEL) (REACH 2017b). In addition, a short-term repeat dose study (OECD 407) in rats orally administered yttrium oxide reported a NOAEL of 480 mg/kg bw/day (highest dose tested) (Panyala et al. 2019). Based on the available acute and short-term toxicity data, acute and sub-chronic (short-term or infrequent) exposure to yttrium-containing substances are not likely to cause adverse health effects in humans.

Risk characterization

On the basis of the available information on this substance, i.e., low detection of total yttrium in biomonitoring data (whole blood), and no substance-specific consumer uses identified (including infrequent use products), exposure to yttrium oxide is expected to be minimal in the general population. For reasonably large population samples, such as CHMS, it is reasonable to assume that the population distribution appropriately captures the variability in biomarker concentrations, even for short half-life substances. Thus,

yttrium oxide in this assessment is of low concern to the health of the general population of Canada at current levels of exposure.

5.2 Biomonitoring-based Approach 2

This science approach incorporates biomonitoring data from large population level biomonitoring programs with a human biomonitoring guidance value (e.g., Biomonitoring Equivalents (BEs), and/or human biomonitoring values (HBM-I) from Germany) to identify substances of low concern for human health.

Similar to Biomonitoring-based Approach 1, Biomonitoring-based Approach 2 considers available Canadian and U.S. biomonitoring data based on the analysis of the substance or moiety in whole blood, serum, and/or urine. Total concentrations of a substance in blood or urine may provide a biologically relevant, integrated measure of exposures that may occur across multiple routes (e.g., oral, dermal and inhalation) and sources, including environmental media, diet, and frequent or daily use products to which they were exposed. The Biomonitoring-based Approach 2 also incorporates health effects data relevant to humans in the assessment of risk. Human biomonitoring guidance values are typically derived from existing health-based exposure guidance values, such as a reference dose (RfD) or tolerable daily intake (TDI) and/or pharmacokinetic data. In some cases, the human biomonitoring guidance values are based on human studies or epidemiological data.

A thorough review of available toxicokinetic data is an integral part of Biomonitoring-based Approach 2. A literature search on toxicokinetic data available on each individual substance in the grouping was conducted. In the absence of kinetic data for the substance (CAS RN), the kinetic data from studies conducted on the metal moiety was used as a surrogate. Biomonitoring-based Approach 2 is only recommended for use if the biomarker (i.e., chemical concentration in whole blood, plasma, serum or urine) is considered adequate to quantify exposure in the general population. Bismuth and lithium-containing substances were assessed under Biomonitoring-based Approach 2. Epidemiology studies conducted in the 1970s reported that oral administration of bismuth as a treatment for GI tract disorders could cause health effects in individuals. Therefore, quantification of risk under Biomonitoring-based Approach 2 was utilized as a more protective approach for the risk assessment of bismuth-containing substances than the qualitative assessment under Biomonitoring-based Approach 1. Biobank data indicated that lithium was detected [$>$ limit of detection (LOD)] in approximately 66% of the general population of Canada. Therefore, lithium-containing substances were assessed under Biomonitoring-based Approach 2.

If exposures (on the basis of biomonitoring data from large-scale studies) are below the human biomonitoring guidance value (on the basis of an RfD, TDI or other critical health effects), then the substance or metal moiety is considered to be of low concern to human health at current levels of exposure.

Uncertainties of Biomonitoring-based Approach-2

Uncertainties associated with this approach have been outlined in the Biomonitoring-based Approach 2 SciAD (Health Canada 2016b).

Although the CHMS biobank data are representative of the general population, CHMS is not a targeted survey and therefore it does not necessarily capture subpopulations which may have different exposures such as those associated with living in the vicinity of industrial facilities. Concluded cycles of CHMS also do not cover children under 3 years of age.

The CHMS cycle 2 biomonitoring data is representative of exposure during 2009 to 2011 in Canada. However, the use pattern analysis did not show any significant change in sources and uses for the substances included in this assessment from the time the CHMS survey was conducted to the present. Thus, it is likely that the biomonitoring data represent current levels of exposure, but do not capture exposures from potential future uses.

In the absence of substance specific kinetic, health effects and exposure data, data available on the metal moiety was used as a surrogate. It is important to note that there may be different bioavailability and health effects associated specific substance versus the metal moiety, in particular with soluble and insoluble substances.

Twenty-three substances met the criteria for being assessed using Biomonitoring-based Approach 2.

5.2.1 Bismuth-containing substances (7 CAS RNs)

Exposure assessment

In the absence of substance specific exposure information, data on the bismuth moiety were used as surrogate exposure data for the specific bismuth-containing substances in the assessment. Bismuth is a naturally occurring element that is present in environmental media (e.g., air, dust) and food in Canada (Tugulea et al. 2016; Rasmussen 2017; Health Canada [modified 2020b]). The median and 95th percentile of total bismuth concentrations measured in Canada in outdoor air PM_{2.5} samples were 0.21 ng/m³ and 0.86 ng/m³, respectively (n=447). Seventeen percent were below the LOD of 0.04 ng/m³ (Rasmussen 2017). The median and 95th percentile of the personal air PM_{2.5} concentrations were 0.07 ng/m³ and 0.70 ng/m³ (n=445), respectively. Thirty-nine percent were below the LOD of 0.04 ng/m³ (Rasmussen 2017). The median and 95th percentile of the indoor air PM_{2.5} were 0.06 ng/m³ and 0.59 ng/m³ (n=437), respectively. Forty percent were below the LOD of 0.04 ng/m³ (Rasmussen 2017). Bismuth concentrations measured in Canadian urban house dust samples ranged from 0.20 to 21.4 µg/g, with a median of 2.42 µg/g, and a 95th percentile of 21.4 µg/g (n=1025) (Rasmussen 2017). Canadian drinking water samples from various distribution

systems were tested for bismuth and all were below the detection limit of 1.0 µg/L (Tugulea et al. 2016). Average concentrations of bismuth were estimated in various food items in the Canadian Total Diet Study (TDS), which measured bismuth concentrations in foods from both natural and anthropogenic sources by preparing and processing food samples as they would be consumed in an average household (Health Canada 2016c; [modified 2020b]). Based upon results from the 2016, 2017, and 2018 data, the highest bismuth concentration was in hard cheese (0.026 µg/g) followed by processed cheese (0.014 µg/g) and baby food dinners with meat, poultry or eggs 0.014 µg/g (Health Canada [modified 2020b]). Further, using the TDS data, dietary intakes of bismuth were estimated for different age–sex groups of the Canadian population (Health Canada [modified 2011]). According to these results, average dietary intake in Canadians (all ages, males and females) was 0.010 µg/kg bw/day, with the highest intake in the 4-6 months age group at 0.101 µg/kg bw/day (Health Canada [modified 2011]).

Biomonitoring data

A summary of the biomonitoring data for total bismuth in whole blood is provided in Table 5-1 and are used as surrogate exposure data for these specific bismuth-containing substances.

Bismuth was not detected in 95.4% of the Canadian population at the limit of detection of 0.1 µg/L (100 ng/L) (Jayawardene et al. 2021). The median and 95th percentile were below the detection limit.

Health effects assessment

Toxicokinetic data and biomarker adequacy

The focus of the toxicokinetic data review was on the oral route of exposure as this would be the predominant route of potential intake of bismuth-containing substances for the general population. Oral absorption of tripotassium dicitrato bismuthate in humans is very low, amounting to less than 1% of the orally ingested bismuth (Gavey et al. 1989). Investigators have reported a large variation in oral absorption based on inter- and intra-individual differences and the type of bismuth administered (Slikkerveer and de Wolff 1989; Benet 1991; Lacey et al. 1994). Some of these reported variabilities seem to be attributed to the use of different study protocols (Benet 1991; Lacey et al. 1994;). Bismuth absorption decreases with increased administered dose; the bioavailability of bismuth from bismuth subsalicylate in rats for 2 and 250 mg/kg bw was 0.5% and 0.025%, respectively (Slikkerveer and de Wolff 1989).

Bismuth, administered as bismuth subsalicylate, is rapidly absorbed into systemic circulation, with peak blood concentrations observed between 15 to 60 minutes post dosing (Slikkerveer and de Wolff 1989). The blood half-lives of bismuth from oral doses of ranitidine bismuth citrate are tri-phasal, averaging 20 minutes, 11.1 hours, and 20.7

days (Koch et al. 1996a). Other authors have reported plasma half-life of about 5 days for absorbed bismuth in humans (Hardman et al. 1996). According to Koch et al. (1996a), plasma bismuth takes approximately 14 to 28 days to reach a steady state. Previous multiple-dose studies in humans have also shown that bismuth (administered orally as bismuth subcitrate) takes about 7 to 29 days to reach steady state (Froomes et al. 1989). From blood, bismuth is distributed predominantly to the kidneys, followed by the spleen, brain, lungs, and liver (Prino and Klantschnigg 1960).

The main route of elimination for unabsorbed bismuth-containing substances is via the feces, whereas urine is the primary excretion pathway for absorbed bismuth in both humans and animals (Slikkerveer and de Wolff 1989; Koch et al. 1996a). Some of the absorbed bismuth is also eventually eliminated via the feces. In fact, according to Lee (1981), more than 99% of ingested bismuth in humans is excreted in the feces. Urinary elimination of the administered dose in humans has been reported in the range of 0.003% to 0.04% (Bierer et al. 1990; Koch et al. 1996a). Washout profiles in plasma and urine indicated an elimination half-life of approximately 21 days for bismuth (Froomes et al. 1989).

The concentration of bismuth in blood represents bioavailable bismuth, which is the fraction systemically available at the target sites of health effects. A frequent or daily exposure to bismuth can be expected in the general population from the presence of bismuth in diet, consumer products and environmental media (Poddalgoda et al. 2020). Thus, the blood concentration of bismuth is likely at steady state. In addition, when using large population samples, such as CHMS, it is reasonable to assume the biomonitoring data would cover off potential intermittent increases in exposures due to products used by consumers on an infrequent basis. Thus, bismuth blood levels can be considered a suitable biomarker to quantify exposure from all routes to all sources of bismuth.

Health effects data and derivation of biomonitoring equivalent

Bismuth-containing substances, in particular bismuth subsalicylate and colloidal bismuth subcitrate, are widely used medicinally for the treatment of diarrhea and peptic ulcer disease in the GI tract (Bradley et al. 1989). Although the introduction of other effective drugs for reducing gastric secretion (such as histamine H2 antagonists and proton pump inhibitors) has reduced the traditional uses of bismuth salts as a generic gastric remedy, the use of bismuth in helicobacter pylori eradication and in the treatment of traveler's diarrhea remains important (Alkim et al. 2017). However, the medicinal use is limited to treatment of pathologies in the GI tract and systemic absorption is not required for efficacy (Slikkerveer and de Wolff 1989). Although adverse effects of bismuth-induced toxicity are rare, an outbreak of neurotoxicity (reversible encephalopathy) was reported in France and neighbouring countries in the mid 1970s, where people were given various forms of bismuth salts (e.g., bismuth subsalicylate, bismuth subnitrate and bismuth subcarbonate) as a treatment for gastrointestinal effects (Slikkerveer and de Wolff 1989). Another small-scale outbreak of encephalopathy was reported in Australia

during the same time period due to therapeutic use of bismuth salts (Slikkerveer and de Wolff 1989). These patients were exposed to approximately 370 mg Bi/day (Slikkerveer and de Wolff 1989). The encephalopathy was reported only in patients with higher serum bismuth levels (Froomes et al. 1989). In a study of 63 patients with encephalopathy after receiving bismuth therapy, the median plasma concentration of bismuth ranged from 680 to 700 µg/L (Hillemand et al. 1977). Based on these studies, the investigators of this bismuth-induced encephalopathy outbreak concluded that a blood bismuth concentration less than 50 µg/L is a safe level (Hillemand et al. 1977). In addition, reversible nephrotoxicity and osteoarthropathy were also reported for acute and chronic exposure to other forms of bismuth-containing substances. The blood levels of these patients were greater than 150 µg/L (Froomes et al. 1989; Slikkerveer and de Wolff 1989).

US FDA has derived recommended daily oral intake of bismuth subgallate of 200 to 400 mg up to 4 times a day for therapeutic use as an aid to reduce odor from a colostomy or an ileostomy (US FDA 2018). According to this recommendation, the maximum oral daily recommended intake is 848 mg Bi/day for a body weight of 70 kg or 12.1 mg/kg bw/day.

There are no indications of carcinogenicity, genotoxicity, reproductive and developmental effects for bismuth-containing substances.

The whole blood BE value associated with US FDA's recommended daily oral intake was derived using a linear regression analysis and the details of the derivation can be found in Poddalgoda et al. (2020).

The regression was conducted correlating intake with the average plasma concentration obtained from multi-day dosing studies (Figure 5-1). As bismuth takes approximately 7-28 days to reach steady state, short-term or single dosing studies are not suitable to conduct regression analysis. Thus, results from controlled dosing studies from Koch et al. (1996a) and Lacey et al. (1994) were selected to derive the BE (Table 5-2). In Koch et al. (1996a), 18 healthy volunteers were given 800 mg bismuth ranitidine citrate twice daily for 28 days. This dose is equivalent to 470 mg Bi/day. Plasma and urine concentrations were collected at several time points during the first 12-hour period and at day 1, 14, and 28 after the first bismuth ranitidine citrate administration. Lacey et al. (1994) administered 500 mg or 1000 mg ranitidine bismuth twice daily to 12 and 11 volunteers, respectively, for 10 days. The administered doses are equivalent to daily bismuth intake of 301 or 602 mg, respectively. Although the absorption of bismuth could have been influenced by variations of gastric pH by ranitidine, the results are consistent with previous data obtained with tripotassium dicitro bismuthate alone (Froomes et al. 1989). Considering an average body weight of 70 kg (ranged from 52.4 to 91.7 kg), the daily doses were equivalent to 4.3 and 8.6 mg Bi/kg bw/day, respectively.

Bismuth pharmacokinetic parameters were calculated for each individual after the first and last doses of each treatment. The parameters included the maximum plasma

bismuth concentration (C_{\max}), the time to C_{\max} (t_{\max}), the area under the plasma concentration-time curve (AUC) over a 12-hour dosing interval (AUC_T), the total urinary recovery of bismuth over a 12-hour dosing interval, and the corresponding renal clearance (CLR). Haematology, biochemistry and urine analysis were conducted on days 3, 7 and 10 of dosing and 7 days post-dosing.

Table 5-2. Bismuth intake levels and average plasma concentrations in human volunteers based on Koch et al. (1996a) and Lacey et al. (1994).

Study	Bismuth dose (mg Bi/kg bw/day)	Geometric mean plasma concentration (µg/L)
Lacey et al. (1994)	4.3	3.0
Lacey et al. (1994)	8.6	6.2
Koch et al. (1996a)	6.9	3.9




Figure 5-1. Linear correlation between bismuth daily dose (mg/kg/day) and average plasma concentration (µg/L) in humans (Poddalgoda et al. 2020).

The linear regression resulted in the following mathematical relationship:

$$\text{Average plasma concentration (}\mu\text{g/L)} = 0.6657x$$

Where oral intake (x) is in mg/kg bw/day.

The plasma BE value associated with US FDA's acceptable daily intake for specific therapeutic uses (i.e., 12.1 mg Bi/kg bw/day) is 8.1 µg/L.

In a single dosing study, Koch et al. (1996b) reported the bismuth concentration ratio between whole blood and plasma as 0.6.

Thus, the whole blood BE based on the FDA's acceptable daily intake for specific therapeutic uses is 4.9 µg/L, which was derived by applying the conversion factor of 0.6 to the plasma concentration (Podalgoda et al. 2020). The use of this BE is considered conservative in light of the 10-fold higher blood bismuth concentration of 50 µg/L, which is considered as a safe level (Hillemand et al. 1977).

Risk characterization

Exposure to total bismuth in the Canadian population was characterized by whole blood concentration data (Table 5-1). Given the large sample size and steady state of bismuth in whole blood, the derived whole blood BE is considered appropriate to assess all potential exposures from bismuth in environmental media, food and through the use of products containing bismuth. The whole blood BE value of 4.9 µg/L is based on the US FDA's acceptable daily intake for specific therapeutic uses of 12.1 mg Bi/kg bw/day. The median and 95th percentile bismuth concentrations were below the detection limit of 0.1 µg/L in the whole blood of Canadians sampled as part of the CHMS (cycle 2). Using the Biomonitoring Approach 2, the limited detection of total bismuth in whole blood is well below the derived BE value. Based on the information presented, bismuth-containing substances in this assessment (i.e., 7 CAS RNs) are of low concern to the health of the general population of Canada at the current levels of exposure.

Uncertainties

The regression analysis used for the BE derivation is based on a small dataset. However, the studies used for this analysis are controlled dosing studies, where volunteers were exposed to multiple doses for a period sufficient to reach a steady state. The blood samples were extracted and analyzed for bismuth at regular intervals. Therefore, this dataset is considered of high quality and represents steady state conditions. In addition, in the bismuth toxicity (encephalopathy) case studies, much higher blood bismuth concentrations were reported (>680 to 700 µg/L) than those attainable from food, environmental media and products containing bismuth.

5.2.2 Lithium-containing substances (16 CAS RNs)

Exposure Assessment

In the absence of substance specific exposure information, data on the lithium moiety were used as surrogate exposure data for the specific lithium-containing substances in the assessment. Lithium is a naturally occurring element that is present in environmental media (e.g., air, water and dust) and food in Canada (Rasmussen 2017; Tugulea et al. 2016). The median and 95th percentile of total lithium concentrations measured in Canada in outdoor air PM_{2.5} (n=38) were 0.11 ng/m³ and 0.26 ng/m³ respectively. Twenty-six percent of the samples were below the LOD (0.08 ng/m³) (Rasmussen 2017). The median and 95th percentile of personal air PM_{2.5} (n= 38) concentrations were <0.08 ng/m³. Seventy-six percent of the concentrations were below LOD (0.08 ng/m³) (Rasmussen 2017). The median and 95th percentile of Indoor air PM_{2.5} (n= 37) concentrations were <0.08 ng/m³. Seventy-three percent of the concentrations were below the LOD (0.08 ng/m³) (Rasmussen 2017). Minimum, median and 95th percentile of lithium concentrations in Canadian urban house dust (n=1025) were 1.30 µg/g, 6.50 µg/g and 12.9 µg/g respectively (Rasmussen 2017). Canadian drinking water samples at various sites of the distribution systems were tested for lithium concentrations and ranged from 2.5 - 160 µg/L with a median of 2.5 µg/L (n=96) (Tugulea et al. 2016). Lithium is present in minerals in the environment; spodumene, petalite, and amblygonite and lithium can enter the aquatic environment through leaching from these minerals (CCME 2008).

Lithium was an element analysed for in the Canadian Total Diet Study starting in 2016. Based on results from the 2016, 2017 and 2018 TDS, the overall mean and median concentrations of lithium in all food composite samples are 0.025 µg/g and 0.011 µg/g, respectively. Food composites with 3-year mean concentrations greater than 0.1 µg/g were reported for: salt (0.513 µg/g), mineral water (0.280 µg/g), herbs and spices (0.265 µg/g), spinach (0.148 µg/g), melons (0.114 µg/g), tomato sauce (0.110 µg/g) and baking powder (0.101 µg/g) (Health Canada [modified 2020b]). Lithium is not monitored in the U.S. FDA's Total Diet Study program. Lithium has been monitored in the second Total Diet Study conducted in 2006 in France, where the mean dietary intake for lithium was 48.2 µg/day while the 5th and 95th percentile were 14.9 and 93.6 µg/day respectively for adults (18-79 years). For children (3 to 17 years) the mean dietary intake was 19.8 µg/day while the 5th and 95th percentiles were 9.0 and 38.6 µg/day, respectively (ANSES 2011).

Biomonitoring data

Lithium was detected in 66.43% of the Canadian population. The median concentration in the whole blood was 0.47 µg/L (95% CI 0.43 to 0.51 µg/L), and the 95th percentile concentration was 1.3 µg/L (95% CI 1.2 to 1.4 µg/L). A summary of the biomonitoring data for total lithium in whole blood is provided in Table 5-1 and are used as surrogate exposure data for these specific lithium-containing substances. In both males and females, an increase in blood lithium concentration with age was observed. The highest lithium concentration in the Canadian population was in adults aged 60 to 79 years. Overall, blood lithium concentrations were not significantly different in females and males (Jayawardene et al. 2021).

Health effects assessment

Toxicokinetic data and biomarker adequacy

The focus of the toxicokinetic data review was on the oral route of exposure as this would be the predominant route of potential lithium intake for the general population. Lithium is rapidly absorbed from the GI tract, with an oral bioavailability of 80% to 100% (Murphy 2008; Ward et al. 1994).

Once absorbed, lithium is rapidly distributed to blood, with peak plasma concentrations reached between 1-2 hours (Baldessarini and Tarazi 2006). Lithium does not bind to plasma proteins and is distributed in the body as a free ion (Baldessarini and Tarazi 2006; Grandjean and Aubry 2009). The average volume of distribution (Vd) of lithium in humans ranges from 0.7-1.0 L/kg (Baldessarini and Tarazi 2006; Grandjean and Aubry 2009). The Vd of lithium decreases with increasing age due to reduction in total body water and lean body mass (Rej et al. 2014).

The overall organ distribution of lithium in humans has not been well studied (Grandjean and Aubry 2009). As lithium readily passes across all biological barriers, it distributes throughout the body compartments (Ward et al. 1994). Lithium concentration in the plasma is twice that of erythrocytes (Ward et al. 1994). After analysing data from seven blood donors, Clarke et al. (2004) reported that the whole blood:plasma partition coefficient was 0.65. Long-term retention of lithium in bones has also been observed. From bones, lithium is slowly eliminated over several months (Grandjean and Aubry 2009).

The primary excretion pathway for lithium is urine, with approximately 90% to 95% of the absorbed dose excreted in urine (Baldessarini and Tarazi 2006). Clearance via saliva, sweat and feces accounts for less than 5% of total excretion (Baldessarini and Tarazi 2006). The urine elimination of lithium appears to reach steady state after 5-6 days of repeated administration (Baldessarini and Tarazi 2006). The elimination half-life of lithium is approximately 20-24 hours (Baldessarini and Tarazi 2006). The average whole body clearance of lithium is in the range of 0.6 to 2.4 L/hour, with significant inter-individual variation (Grandjean and Aubry 2009). Lithium clearance decreases with age (Grandjean and Aubry 2009).

The concentration of lithium in blood represents the bioavailable fraction, which is the fraction systemically available at the target sites. A steady state lithium concentration in blood can be expected in the general population because of the frequent or daily exposure to lithium from diet, drinking water, consumer products and environmental media (US EPA 2008; Ramoju et al. 2020). In addition, when using large population samples, such as CHMS, it is reasonable to assume the biomonitoring data would cover off potential intermittent increases in exposures due to products used by consumers on an infrequent basis. Thus, blood lithium concentration can be considered as a suitable biomarker to quantify exposure from all routes and all sources of lithium.

Health effects data and derivation of biomonitoring equivalent

Lithium is not considered an essential element; however, some reviewers have suggested that lithium may have beneficial neurological and anti-aging effects in humans (Martone 2018). Lithium salts are prescribed at the recommended daily dose of 167 mg Li/day for treatment of manic-depressive disorders (Barthelmebs et al. 1993; Nordic Expert Group Review 2002). The target serum lithium concentration for optimal therapeutic effects range from 5.6 to 6.9 mg Li/L (0.8 to 1.0 mM Li/L) (US EPA 2008). Lithium toxicity has been observed at serum concentrations ranging from 3.5 mg Li/L (0.5 mM Li/L) to 17.4 mg Li/L (2.5 mM Li/L) or higher (Nordic Expert Group Review 2002). Lithium has a narrow therapeutic index, and adverse side effects can be seen even at therapeutic dose levels (US EPA 2008; Gitlin 2016). Lithium treatment in humans is associated with reduced tubular renal function leading to kidney insufficiency (McKnight et al. 2012; Health Canada 2014; Health Canada 2016c). In addition, hypothyroidism, hyperparathyroidism, and weight gain are also reported (McKnight et al. 2012; Health Canada 2014; Gitlin 2016; Health Canada 2016c). Health Canada (2014) issued a physicians' advisory with the recommendation of monitoring blood calcium levels before and during lithium treatment because lithium treated patients have shown increased incidence of hypercalcemia and hyperparathyroidism. Changes in calcium homeostasis has also been observed in pregnant women (n=178) exposed to elevated concentration of lithium in drinking water (5-16600 µg/L). Median maternal blood lithium concentration was 25 µg/L (range 2.9-145). Blood lithium was inversely associated with 25-hydroxyvitamin D₃ (95% CI -9.5, -2.6) and positively associated with serum magnesium (Harari et al. 2016). In addition, lithium-treated patients show neurological effects, such as tremor, confusion, when serum concentrations are approximately 3.5 mg/L or above (Nordic Expert Group Review 2002). However, lithium induced nephrotoxicity is only reported in prolonged (several years) lithium treatment (Nordic Expert Group Review 2002; US EPA 2008). In contrast, experimental evidence suggests that short-term low doses of lithium may have a kidney-protective effect (Gong et al. 2016; Martone 2018). There are no indications of carcinogenicity, genotoxicity, reproductive and developmental effects for lithium-containing substances (Nordic Expert Group Review 2002; US EPA 2008).

Health Canada (2016c) has adopted a permitted daily exposure (PDE) value for therapeutics for oral lithium exposure derived from the International Council on Harmonisation of Technical Requirements for the Registration of Pharmaceuticals for Human Use (ICH) Guideline for Elemental Impurities- Q3D (ICH 2014). The PDE indicates the maximum permitted quantity of lithium as an impurity in therapeutic products (Health Canada 2016c). ICH (2014) considered a third of the lowest recommended therapeutic daily dose of lithium carbonate (900 mg) as the point of departure (POD) to derive a PDE. Thus, the POD is equivalent to 300 mg lithium carbonate/day (56 mg Li/day). This POD value is equivalent to 0.8 mg Li/kg bw/day, assuming 70 kg body weight. As lithium toxicity may also be observed at therapeutic doses, this POD is considered a lowest observed adverse effect level (LOAEL) by ICH (2014). On the basis of this POD, a safety factor of 100 was applied to account for inter-

individual variability (x10) and use of a LOAEL rather than a NOAEL (x10). The resulting PDE derived by ICH (2014) for lithium is 8 µg Li/kg bw/day.

The US EPA (2008) has developed a Provisional sub-chronic and chronic Peer-Reviewed Toxicity Value (PPRTV) (provisional Reference Dose, p-RfD) for lithium to protect against adverse effects (mainly renal toxicity) of excess lithium exposure via the oral route. US EPA (2008) derived a LOAEL of 2.1 mg Li/kg bw/day using the lower bound values of the therapeutic serum lithium concentration range (0.6 mmol/L), lithium plasma clearance (0.5 L/kg day) and 100% absorption. An uncertainty factor of 1000 was applied to the LOAEL to account for database deficiencies (x10), inter-individual variability (x10) and the use of a LOAEL rather than a NOAEL (x10), resulting in a RfD of 2 µg Li/kg bw/day. The PDE value derived by ICH (2014) and adopted by Health Canada (2016c) is considered the most appropriate exposure guidance value for risk characterization as the guidance value (i.e., PDE) is based on a more conservative POD than the US EPA's PPRTV.

The whole blood BE value associated with the PDE was derived using a simple kinetic equation and the details of the derivation can be found in Ramoju et al. (2020).

The steady-state plasma concentration of lithium (i.e., BE_{POD}) associated with the POD of 0.8 mg Li/kg bw/day was computed by applying a clearance value and the fraction of the dose absorbed as follows (US EPA 2008):

$$\text{BE}_{\text{POD}} (\text{mg Li/L plasma}) = [\text{POD} (\text{mg Li/kg bw/day})] * [\text{Fraction absorbed}] / \text{Clearance} (\text{L/kg bw/day})$$


A whole body clearance value of 0.5 L/kg bw/day and 100% absorption was applied for the BE derivation based on published literature (US EPA 2008).

A steady state plasma BE for lithium was derived by applying uncertainty factors to the BE_{POD}. The plasma BE was multiplied by the whole blood:plasma partition coefficient of 0.65 to derive a steady state whole blood BE. The whole blood BE for the PDE was 10.4 µg Li/L (Ramoju et al. 2020)

Risk characterization

Exposure to total lithium in the Canadian population was characterized by whole blood concentration data (Table 5-1). Given the large sample size and steady state of lithium in whole blood, the derived whole blood BE is considered appropriate to assess all potential exposures from lithium in environmental media and through the use of products containing lithium. The BE is based on ICH's PDE value of 8 µg Li/kg bw/day, for therapeutics and which was adopted by Health Canada (2016c). The whole blood concentration data and BE for lithium are compared in Figure 5-2. The median and the 95th percentile whole blood concentrations for different age groups of the Canadian general population, obtained from the CHMS cycle 2 (represented in bars and whiskers,

respectively in Figure 5-2), are well below the BE value of 10.4 µg/L. Using the Biomonitoring Approach 2, the whole blood concentrations detected for lithium are well below the derived BE, which suggests that the lithium-containing substances in this assessment (i.e., 16 CAS RNs) are of low concern to the health of the general population of Canada at current levels of exposure.



* The median value for age group 12 to 19 was too unreliable to be published.

Figure 5-2. Comparison of the median (bar) and the 95th percentile (whiskers) of the concentrations of whole blood lithium (µg/L) from the CHMS- cycle 2 (2009-2011) biobank with the biomonitoring equivalent of 10.4 (µg/L) for PDE value (ICH 2014) (indicated by a solid line).

Uncertainties

There is some uncertainty in lithium clearance in various age groups in the general population because there is less clearance per body weight expected in children and the elderly population. However, when deriving exposure guidance values, both ICH

(2014) and US EPA (2008) assigned an uncertainty factor to account for intra-individual variations.

There is also some uncertainty when deriving whole blood BE using plasma BE. However, since the whole blood:plasma partitioning coefficient was derived using data from human studies, there is a high confidence in this value. There is low to moderate confidence in whole blood concentration as a biomarker to quantify exposure due to rapid elimination from blood (peak concentration is reached within 1-2 hours after exposure).

5.3 Rapid Screening of Substances with Limited General Population Exposure

The Rapid Screening of Substances with Limited General Population Exposure for Human Health is used to identify low concern substances by evaluating the potential for direct exposure from products and, as needed, indirect exposure from environmental media. The human health portion of this rapid screening approach consists of multiple steps which are outlined in the publication (ECCC, HC [modified 2018]). The first step is to determine if a candidate substance has the potential for direct exposure from products used by the general population of Canada. If there is no potential for direct exposure, then the substance proceeds to the second step whereby the potential for indirect exposure from environmental media is examined. If the estimated exposure is negligible (<2.5 ng/kg bw/day), then the candidate substance is considered to have a low potential for exposure.

Sodium bromate was considered in the Rapid Screening of Substances with Limited General Population Exposure Assessment (ECCC, HC 2018); however, it was identified as requiring further assessment due to the potential for direct exposure from the use of cosmetic products. Sodium bromate was previously found in a small number of cosmetic products as a restricted ingredient on the Hotlist. However, the Hotlist was recently revised to describe sodium bromate as prohibited for use in cosmetics (Health Canada [modified 2019]). As a result, with these uses removed, there should no longer be potential for direct exposure to the general population of Canada from cosmetic products. Sodium bromate may be used as a component in the manufacture of food packaging materials and incidental additives used in food processing establishments; dietary exposure from these uses are not expected as the substance is not in direct contact with food (personal communication, email from the Food Directorate, Health Canada, to the Existing Substances Risk Assessment Bureau, Health Canada, dated September 28, 2017; unreferenced).

In the absence of direct exposure to a substance for the general Canadian population, the approach considers indirect exposure from various environmental media. There is limited data on measured or predicted concentrations or releases of sodium bromate in environmental media (i.e., soil, air, water). Bromate has been found in drinking water as

a result of water treatment, rather than through source water contamination (Health Canada 2019). The contribution of sodium bromate to drinking water is expected to be negligible. Similar to potassium bromate, exposure to sodium bromate from environmental media is expected to be negligible (EC, HC 2010).

On the basis of the evaluation of both direct and indirect exposure conducted as part of this rapid screening approach, exposure of the general population to sodium bromate is considered to be minimal and is of low concern to the human health in Canada at current levels of exposure.

6. Conclusion

Considering all available lines of evidence presented in this draft screening assessment, there is low risk of harm to the environment from the 34 substances in this assessment. It is proposed to conclude that these substances do not meet the criteria under paragraphs 64(a) or (b) of CEPA as they are not entering the environment in a quantity or concentration or under conditions that have or may have an immediate or long-term harmful effect on the environment or its biological diversity or that constitute or may constitute a danger to the environment on which life depends.

Considering all of the information presented in this draft screening assessment, it is proposed to conclude that the 34 substances in this assessment do not meet the criteria under paragraph 64(c) of CEPA as they are not entering the environment in a quantity or concentration or under conditions that constitute or may constitute a danger in Canada to human life or health.

It is therefore proposed to conclude that the 34 substances in this assessment do not meet any of the criteria set out in section 64 of CEPA.

References

- Agnew WF. 1972. Transplacental uptake of ^{127m}Tellurium studies by whole-body autoradiography. *Teratology*. 6(3):331-337.
- Agnew WF, Cheng JT. 1971. Protein binding of tellurium-^{127m} by maternal and fetal tissues of the rat. *Toxicol Appl Pharm*. 20(3):346-356.
- Agnew WF, Fauvre FM, Pudenz PH. 1968. Tellurium hydrocephalus: distribution of tellurium-^{127m} between maternal, fetal, and neonatal tissues of the rat. *Exp Neurol*. 21(1):120-131.
- Alkim H, Koksar AR, Boga S, Sen I, Alkim C. 2017 Role of bismuth in the eradication of *Helicobacter pylori*. *Am J Ther*. Nov/Dec;24(6):e751-e757.
- [ANSES] French agency for food, environmental and occupational health and safety. 2011. Second French Total Diet Study (TDS 2) Report 1: Inorganic contaminants, minerals, persistent organic pollutant, mycotoxins and phytoestrogens.
- Baldessarini RJ, Tarazi FI. 2006. Chapter 18. Pharmacotherapy of psychosis and mania. In: Goodman and Gilman's *The Pharmacological Basis of Therapeutics*. L.L. Brunton, J.S. Lazo and K.L. Parker, editors. Eleventh edition. McGraw Hill Inc.; New York, NY.
- Barthelmebs M, Ehrhardt JD, Schweitzer-Ehret A, Danion JM, Imbs JL. 1993. [Erythrocyte/plasma ratio of lithium. Determination method and individual stability]. *Encephale*. 19:321-327.
- Behets G J, Mubiana K V, Lamberts L, Finsterle K, Traill N, Blust R. ^b Patrick C. D'Haese P C. 2020. 7. Use of lanthanum for water treatment A matter of concern?, *Chemosphere* 239: 1-10.
- Bradley B, Singleton M, Lin Wan Po A. 1989. Bismuth toxicity--a reassessment. *J Clin Pharm Ther*. Dec;14(6):423-41.
- Benet LZ. 1991. Safety and pharmacokinetics: colloidal bismuth subcitrate. *Scand J Gastroenterol Suppl*. 185, 29-35.
- Bierer DW. 1990. Bismuth Subsalicylate: History, Chemistry, and Safety. *Rev Infect Dis*. 12, S3-S8.
- Bjondahl K. 1976. Differences in liver weight, mortality in cerium-treated mice and ¹⁴⁴Ce levels in blood, liver, urine and faeces at various intervals after treatment with nafenopin and pregnenolone 16- α -carbonitrile (PCN). *Med Biol*. 54, 454-460.
- Bouchard M, Krishnan K, Dieme D, Côté J. 2017. Animal studies to support the interpretation of biomonitoring data for rare-earth metals. Unpublished report. Montreal (QC). University of Montreal Public Health Research Institute (IRSPUM).
- Browning E. 1969. Germanium. In *Toxicity of Industrial Metals*, (New York: Appleton-Century-Crofts) pp. 159.
- Canada. 1999. Canadian Environmental Protection Act, 1999. S.C. 1999, c.33. Canada Gazette Part III, vol. 22, no. 3.

Canada. 2009. *Canadian Environmental Protection Act, 1999: Notice with respect to certain inanimate substances (chemicals) on the Domestic Substances List (PDF)*. Canada Gazette, Part I, vol. 143, no. 40, p. 2945-2956.

Canada 2012 Dept. of the Environment. 2012. *Canadian Environmental Protection Act, 1999: Notice with respect to certain substances on the Domestic Substances List*. Canada Gazette, Part I, vol. 146, no. 48.

CBSA [Canada Border Services Agency]. 2016. Information gathered on the import of commodities corresponding to the codes HC 2825200020, HS 2836900090. Confidential information.

CCME [Canadian Council of Ministers of the Environment] 2008. *Canadian Water Quality Guidelines (PDF)*. Ottawa (ON): Environment Canada.

Clarke WB, Guscott R, Downing RG, Lindstrom RM. 2004. Endogenous lithium and boron red cell-plasma ratios: normal subjects versus bipolar patients not on lithium therapy. *Biol Trace Elem Res*. 97(2):105-116.

CPCat [Chemical and Product Categories]. 2017. Exploring Consumer Exposure Pathways and Patterns of Use for Chemicals in the Environment. *Toxicology Reports* 2: 228-237. Curated chemical and product categories data were retrieved from the CPCat Database, U.S. EPA, RTP, NC. [accessed 2018 February 14]

CPID [Consumer Product Information Database] [database] 2018. 2001-2018. McLean (VA): DeLima Associates. [accessed 2018 10 22].

Curran MP, Robinson DM. 2009. Lanthanum carbonate: A review of its use in lowering serum phosphate in patients with end-stage renal disease. *Drugs*. 69(16): 2329-2349.

Dammett SJ, Pennick M. 2007. Systemic lanthanum is excreted in the bile of rats. *Toxicol Lett*. 171 (1-2):69-77.

Dammett SJ, Pennick M. 2008. Clinical pharmacokinetics of the phosphate binder lanthanum carbonate. *Clin Pharmacokinet*. 47:553-563.

Dudley HC, Wallace EJ. 1952. Pharmacological studies of radiogermanium (GE71). *AMA Arch Ind Hyg Occup Med*. 6:263-270.

Dudley HC. 1953. Pharmacological Studies of Radiogermanium (Ge 71). *Arch Industr Hyg*.8:528

EC, HC [Environment Canada, Health Canada]. 2010. *Screening Assessment for the Challenge. Bromic Acid, Potassium salt (Potassium Bromate): Chemical Abstracts Service Registry Number 7758-01-2 (PDF)*. Ottawa (ON): Government of Canada.

EC, HC [Environment Canada, Health Canada]. 2013. *Rapid screening of substances of lower concern: results of the screening assessment*. Ottawa (ON): Government of Canada.

EC, HC [Environment Canada, Health Canada]. 2014. *Rapid screening of substances from phase one of the Domestic Substances List inventory update: results of the final screening assessment*. Ottawa (ON): Government of Canada.

ECCC, HC [Environment and Climate Change Canada, Health Canada. 2016. Rapid screening of substances identified from phase two of the Domestic Substances List inventory update: results of the screening assessment. Ottawa (ON): Government of Canada.

ECCC, HC [Environment and Climate Change Canada, Health Canada]. [modified 2018]. Rapid Screening of Substances with Limited General Population Exposure. Ottawa (ON): Health Canada. [accessed 2019 December].

ECCC, HC [Environment and Climate Change Canada, Health Canada]. [modified 2017]. Categorization. Ottawa (ON): Government of Canada. [accessed 2018 October].

ECCC [Environment and Climate Change Canada]. [modified May 4 2018]. Science Approach Document: Ecological Risk Classification of Inorganic Substances. Gatineau (QC).

Lanthanum chloride, anhydrous. European Union. Helsinki, Finland Environment Canada. 2009. DSL Inventory Update data collected under the *Canadian Environmental Protection Act, 1999*, section 71: *Notice with respect to certain inanimate substances (chemicals) on the Domestic Substances List*. Data prepared by Environment Canada, Health Canada; Existing Substances Program.

Environment Canada. 2013. DSL Inventory Update data collected under the *Canadian Environmental Protection Act, 1999*, section 71: *Notice with respect to certain substances on the Domestic Substances List*. Data prepared by Environment Canada, Health Canada; Existing Substances Program.

Feng L, Xiao H, He X, Li Z, Li F, Liu N, Chai Z, Zhao Y, Zhang Z. 2006a. Neurotoxicological consequence of long-term exposure to lanthanum. *Toxicol. Letters*. 165(2): 112-120.

Feng L, Xiao H, He X, Li Z, Li F, Liu N, Zhao Y, Huang Y, Zhang Z, Chai ZL. 2006b. Long-term effects of lanthanum intake on the neurobehavioral development of the rat. *Neurotoxicology and Teratology* 28: 119-124.

Froome PRA, Wan AT, Keech AC, McNeil JJ, McLean AJ. 1989. Absorption and elimination of bismuth from oral doses of tripotassium dicitrate bismuthate. *Eur J Clin Pharmacol*. 37:533-536.

Gavey CJ, Szeto ML, Nwokolo CU, Sercombe J, Pounder RE. 1989. Bismuth accumulates in the body during treatment with tripotassium dicitrate bismuthate. *Aliment Pharmacol Ther*. Feb;3(1):21-8.

Gerhardsson L. 2015. Chapter 54 - Tellurium A2 - Nordberg, Gunnar F. In: Fowler BA, Nordberg M (eds) *Handbook on the Toxicology of Metals* (Fourth Edition). Academic Press, San Diego, p 1217-1228.

Gitlin M. 2016. Lithium side effects and toxicity: prevalence and management strategies. *Int J Bipolar Disord*. 4:27

Gong R, Wang P, Dworkin L. 2016. What we need to know about the effect of lithium on the kidney. *Am J Physiol Renal Physiol* 311: F1168–F1171.

Grandjean EM, Aubry JM. 2009. Lithium: updated human knowledge using an evidence-based approach. Part II: Clinical pharmacology and therapeutic monitoring. *CNS Drugs*. 23:331-349.

Harari F, Åkesson A, Casimiro E, Lu Y, Vahter M. 2016. Exposure to lithium through drinking water and calcium homeostasis during pregnancy: A longitudinal study. *Environ Res*. 147: 1-7.

Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Goodman AG (eds.). 1996. Goodman and Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill, p. 910

Hayashi S, Usuda K, Mitsui G, Shibutani T, Dote E, Adachi K, Fujihara M, Shimbo Y, Sun W, Kono R, et al. 2006. Urinary yttrium excretion and effects of yttrium chloride on renal function in rats. Biol Trace Element Res. 114(1-3):225-235.

He X, Zhang Z, H. Zhang, Zhao Z, Chai Z. 2008. Neurotoxicological evaluation of long-term lanthanum chloride exposure in rats. Toxicol. Sci. 103 (2): 354-361

Health Canada. 2010. [Report on Human Biomonitoring of Environmental Chemicals in Canada. Results of the Canadian Health Measures Survey Cycle 1 \(2007-2009\)](#). August 2010. Ottawa (ON): Health Canada. [Accessed 2019 Nov].

Health Canada. 2013. [Second Report on Human Biomonitoring of Environmental Chemicals in Canada. Results of the Canadian Health Measures Survey Cycle 2 \(2009-2011\)](#). April 2013. Ottawa (ON): Health Canada. [accessed 2019 Nov].

Health Canada. 2014. New safety information. [Lithium - Risk of Hypercalcemia and Hyperparathyroidism - For Health Professionals](#). Ottawa, (ON): Marketed Health Products Directorate, Health Canada. [accessed 2019 July].

Health Canada. 2015. [Third Report on Human Biomonitoring of Environmental Chemicals in Canada. Results of the Canadian Health Measures Survey Cycle 3 \(2012-2013\)](#). July 2015. Health Canada. 2015. Bromate in Drinking Water consultation document. Ottawa (ON): Federal-Provincial-Territorial Committee on Drinking Water

Health Canada. 2016a. [Science Approach Document. Biomonitoring-based Approach 1 for Beryllium, Vanadium, trichlorooxo and Vanadium oxide](#). Ottawa (ON): Health Canada. [accessed 2018 Sept].

Health Canada. 2016b. [Science Approach Document. Biomonitoring-based Approach 2 for Barium-containing Substances, Molybdenum-containing Substances, Silver-containing Substances, Thallium-containing Substances and Inorganic Tin-containing Substances](#). Ottawa (ON): Health Canada. [accessed 2018 Sept].

Health Canada. 2016c. Q3D Notice: Guideline for Elemental Impurities. Adoption of International Conference on Harmonisation of Technical Requirements for the Registration of Pharmaceuticals for Human Use (ICH) Guidance Document. [accessed 2019 July].

Health Canada. 2017. [Fourth Report on Human Biomonitoring of Environmental Chemicals in Canada. Results of the Canadian Health Measures Survey Cycle 4 \(2014-2015\)](#). August 2017. File number: 16-100030-245. January 29, 2016. Ottawa (ON): Health Products and Food Branch, Health Canada. [Unpublished document].

Health Canada. 2019. [Guidelines for Canadian Drinking Water Quality. Guideline Technical Document. Bromate](#). Ottawa (ON): Health Canada. [accessed 2021 May].

Health Canada. [modified 2011 Jan 19]. [Average dietary intakes \(µg/kg bw/d\) of trace elements for Canadians in different age/sex groups for Total Diet Study in 2007](#). Ottawa (ON): Health Canada [accessed April 2019]

[modified 2019 Dec 3]. Cosmetic ingredient hotlist: list of ingredients that are prohibited for use in cosmetic products. Ottawa (ON): Health Canada, Consumer Product Safety Government of Canada. [accessed 2020 Jan].

Health Canada. [modified 2020a December 10]. The Canadian Health Measures Survey. Ottawa (ON): Health Canada. [Accessed 2020 Jan 12].

Health Canada. [modified 2020b November 24]. Concentration of Contaminants and Other Chemicals in Food Composites. 2020. Concentration of Contaminants and Other Chemicals in Food Composites. Ottawa (ON): Health Canada [accessed 2021 February]

Hillemand P, Palliere M, Laquis B, Bouvet P. Traitement bismuthique et bismuthemie. Sem Hop Paris 1977; 53: 1663-9.

Hirano S, Kodama N, Shibata K, Suzuki KT. 1990. Distribution localization and pulmonary effects of yttrium chloride following intratracheal instillation into the rat. Toxicol Appl Pharmacol. 104(2):301-311.

Hirano S, Kodama N, Shibata K, Suzuki KT. 1993. Metabolism and toxicity of intravenously injected yttrium chloride in rats. Toxicol Appl Pharmacol. 121(2):224-232.

Hollins JG. 1969. The metabolism of tellurium in rats. Health Phys. 17(3):497-505. HSDB [Hazardous Substances Data Bank] (2009). Tellurium. Toxicity Effects CAS Registry Number: 13494-80-9, U.S. National Library of Medicine [online], Bethesda, USA. [ICH] International council for harmonisation of technical requirements for pharmaceuticals for human use. 2014 (updated in 2019). ICH harmonised guideline for elemental impurities Q3D. [Accessed Oct 2019].

ICRP [International Commission on Radiological Protection]. 1981. ICRP Publication 30 PART 3: Limits for Intakes of Radionuclides by Workers. Annals of the ICRP, 6, (2/3) 50-52.

ICRP [International Commission on Radiological Protection]. 1994. ICRP Publication 68: Dose Coefficients for Intakes of Radionuclides by Workers. Annals of the ICRP, 24, (4).

Inaba J, Suzuki-Yasumoto M. 1979. A kinetic study of radionuclide absorption through damaged and undamaged skin of the guinea pig. Health Phys. 37(4): 592-595.

Jayawardene I, Paradis J-F, Belisle S, Poddalgoda D, Macey K. 2021. Multi-elemental determination of metals, metalloids and rare earth element concentrations in whole blood from the Canadian Health Measures Survey, 2009-2011. J Trace Elem Med Biol. 68: 126830

Kobayashi A, Ogra Y. 2009. Metabolism of tellurium, antimony and germanium simultaneously administered to rats. J Toxicol Sci. 34(3): 295-303.

Kitamura Y, Usuda K, Shimizu H, Fujimoto K, Kono R, Fujita A, Kono K. 2012. Urinary Monitoring of Exposure to Yttrium, Scandium, and Europium in Male Wistar Rats. Biol Trace Elem Res. 150(1-3):322-327.

Koch KM, Kerr BM, Gooding AE, Davis IM. 1996a. Pharmacokinetics of bismuth and ranitidine following multiple doses of ranitidine bismuth citrate. Br J Clin Pharmacol. 4(2):207-211.

Koch KM, Davis IM, Gooding AE, Yin Y. 1996b. Pharmacokinetics of bismuth and ranitidine following single doses of ranitidine bismuth citrate. Br J Clin Pharmacol. 42(2):201-5.

Kunasz I, 2006. Industrial Minerals & Rocks. Society for Mining, Metallurgy, and Exploration, Inc. Colorado.ed 7. p 599-613.

Kron T, Hansen C, Werner E. 1991a. Renal excretion of tellurium after peroral administration of tellurium in different forms to healthy human volunteers. J Trace Elem Electrolytes Health Dis. 5(4):239-244

Kron T, Hansen C, Wernert E. 1991b. Tellurium ingestion with foodstuffs. J Food Compos Anal. 4(3):196-205.

Lambert CE, Barnum EC, Shapiro R. 1993. Acute toxicological evaluation of yttrium oxide. J Am Coll Toxicol. 12(6), 630.

Lacey LF, Frazer NM, Keene ON, Smith JTL. 1994. Comparative pharmacokinetics of bismuth from ranitidine bismuth citrate (GR122311X), a novel anti-ulcerant and tripotassium dicitrato bismuthate (TDB). Eur J Clin Pharmacol. 47:177-180.

Lee SP. 1981. Studies on the absorption and excretion of tripotassium dicitrato-bismuthate in man. Res Commun Chem Pathol Pharmacol. 34:359-364.

LNHPD [Licensed Natural Health Products Database]. [modified 2018 Feb 6]. Ottawa (ON): Government of Canada. [accessed 2019 August 20].

MAK. [Maximale Arbeitsplatz-Konzentration] (maximum workplace concentration). 2006. The MAK Collection for Occupational Health and Safety. Tellurium and its inorganic compounds.

Marroum P, Dorantes A. 2004. Clinical pharmacology and biopharmaceutics review, Division of pharmaceutical evaluation I, NDA 21-468.

Martone G. 2018. Nutritional lithium. J Clin Psychiatry Neurosci. 1(1):1-4.

McKnight RF, Adida M, Budge K, Stockton S, Goodwin G, Geddes J. 2012. Lithium toxicity profile: a systematic review and meta-analysis. Lancet. 379(9817):721-8.

Miyao K, Onishi T, Asai K, Tomizawa S, and Suzuki, F. 1980. Toxicology and phase I studies on a novel organogermanium compound, Ge-132. Curr Chemother Infect Dis. 2:1527–1529.

Mohammed I, Hutchison AJ. 2009. Oral phosphate binders for the management of serum phosphate levels in dialysis patients. J Ren Care, 35 Suppl 1, 65-70.

Mortelmans K, Haworth S, Lawlor T, Speck W, Tainer B, Zeiger E. 1986. Salmonella mutagenicity tests. II. Results from the testing of 270 chemicals. Environ Mutagen. 8(7): 1-119.

Moskalev YI. 1959. Experiments on the distribution of cerium-144. Med. Radiol. 4, 52-7.

Murphy JE. Clinical pharmacokinetics. 2008. Bethesda: American Society of Health-System Pharmacists, Inc.

NAPS [National Air Pollution Surveillance Network]. 2015. [pre-publication NAPS data on Excel spreadsheet]. Ottawa (ON): Environment Canada, Analysis and Air Quality Division. [unpublished data].

- Nakamura Y, Tsumura-Hasagawa Y, Tonogai Y, Kanamoto M, Tsuboi N, Murakami K, Ito Y. 1991. Excretion of dysprosium, Europium, Ytterbium and Yttrium in the rat after oral administration. *Eisei Kagaku*. 37(5):418-425.
- Nakamura Y, Tsumura Y, Tonogai Y, Ito Y. 1993. Studies on the biological effects of rare earth elements: V. Relationship between the concentration of rare earth elements and 9 minerals in various organs in the rat after intravenous administration of dysprosium, europium, ytterbium and yttrium by low or high dose. *Japanese J Toxicol Environ Health*. 39(2):121-131.
- Needham L, Sexton K. 2000. Introduction and overview: Assessing children's exposure to hazardous environmental chemicals: an overview of selected research challenges and complexities. *J Expo Sci Environ Epidemiol* 10 611–629
- Nordic Expert Group Review. 2002. Criteria Documentation of Health Risks from Chemicals. 131. Lithium and lithium compounds [PDF]. Nordic Council of Ministers. National Institute for Working life. 2002. [accessed 2019 July]
- NRC [National Research Council]. 2006. Human Biomonitoring for Environmental Chemicals. Washington (DC): The National Academies Press.
- NTP [National Toxicology Program]. 1979. Bioassay of ethyl tellurac for possible carcinogenicity [PDF]. Bethesda (MD): U.S. Department of Health, Education, and Welfare, National Institutes of Health.
- Ogra Y, Kobayashi R, Ishiwata K, Suzuki KT. 2007. Identification of urinary tellurium metabolite in rats administered sodium tellurite. *Journal of Analytical Atomic Spectrometry* 22(2):153-157.
- Ohri LK, Vicari SM and Malone PM. 1993. Germanium use and associated adverse effects: a review. *J Pharm Technol*. 9:237-241.
- Panyala A, Schinde S, Kumari SI, Grover P. Assessment of genotoxicity and biodistribution of nano- and micron-sized yttrium oxide in rats after acute oral treatment. *J Appl Toxicol*. 37: 1379-1395.
- Panyala A, Schinde S, Kumari SI, Rahman MF, Mahboob M, Kumar JM, Grover P. 2019. Comparative study of toxicological assessment of yttrium oxide nano- and microparticles in Wistar rats after 28 days of repeated oral administration. *Mutagenesis*. 34: 181-201.
- Pennick M, Dennis K, Damment SJ. 2006. Absolute bioavailability and disposition of lanthanum in healthy human subjects administered lanthanum carbonate. *J Clin.Pharmacol*. 46(7):738-746.
- Poddalgoda D, Hays S, Nong A. 2020. Biomonitoring Equivalents for Bismuth. *Reg Toxicol Pharmacol*. 114: 104672.
- Pawel DJ, Leggett RW, Eckerman KF, Nelson CB. 2007. Uncertainties in Cancer Risk Coefficients for Environmental Exposure to Radionuclides. An Uncertainty Analysis for Risk Coefficients Reported in Federal Guidance Report No. 13. U.S. Department of Energy (DOE), Springfield, VA.
- Prino G, Klantschnigg P. 1960. Research on bismuth-lecithin camphorcarboxylate. 1. Absorption, distribution and elimination of the bismuth after treatment of the healthy rat with a single dose. *Arch. Sci. Med. (Torino)* 110: 370-382.

Ramoju S, Andersen M, Poddalgoda D, Karyakina N, Shilnikova N, Krishnan K, Nong A, Krewski D. 2020. Derivation of whole blood biomonitoring equivalents for lithium for the interpretation of biomonitoring data. *Reg Toxicol Pharmacol*. 111: 1-7.

Rao J, Wu C, Yue, K. 1992. Some recent work on resampling methods for complex surveys. *Survey Methodology*, 18 : 209–217

Rasmussen PE. 2017. Preliminary Canadian exposure data for seven elements Al, Bi Cr, Ge, Li, Te, and Ti. CMP(3) Research. August 16, 2017. Ottawa (ON): Exposure and Biomonitoring Division, Health Canada [personal communication, unpublished data].

Rasmussen PE, Levesque C, Chénier M, Gardner HD. 2017. Rare earth elements and select actinoids in the Canadian House Dust Study *International Journal of Indoor Environment and Health - Indoor Air*. 27:965–976.

Rasmussen, PE, Levesque, C, M Chénier, M, Gardner, HD. 2018 Contribution of metals in resuspended dust to indoor and personal inhalation exposures: Relationships between PM10 and settled dust. *Building and Environment* 143: 513-522. doi.org/10.1016/j.buildenv.2018.07.044

Rasmussen PE. 2019. Ottawa (ON): Exposure and Biomonitoring Division, Health Canada [personal communication, unpublished data].

Rej S, Beaulieu S, Segal M, Low NCP, Mucsi I, Holcroft C, Shulman K, Looper KJ. 2014. Lithium dosing and serum concentrations across the age spectrum: From early adulthood to the tenth decade of life. *Drugs Aging*. 31:911-916.

REACH [Registration, Evaluation, Authorisation and Restriction of Chemicals]. 2017a. Registration (REACH) dossier for Tellurium (CASRN 13494-80-9). First published: 16-Jul-2013. Last modified: 22-Nov-2017. [accessed 2019 October].

REACH [Registration, Evaluation, Authorisation and Restriction of Chemicals]. 2017b. Registration (REACH) dossier for Yttrium oxide (CASRN 1314-36-9). First published: 16-Jul-2013. Last modified: 22-Nov-2017. [accessed 2019 October].

REACH [Registration, Evaluation, Authorisation and Restriction of Chemicals]. 2018a. Registration (REACH) dossier for Diprasedymium trioxide (CASRN 12036-32-7). First published: 22-Feb-2018. Last modified: 21-Feb-2018. [accessed 2021 June].

REACH [Registration, Evaluation, Authorisation and Restriction of Chemicals]. 2018b. Lanthanum chloride, anhydrous (CAS RN 10099-58-8). First published: 18-Mar-2011. Last modified: 15-May-2018. [accessed September 2019].

REACH [Registration, Evaluation, Authorisation and Restriction of Chemicals]. 2018c. Registration (REACH) dossier for Tetrakis(diethyldithiocarbamate-S,S')tellurium (CASRN 20940-65-5). First published: 05-Feb-2019. Last modified: 04-Oct-2018. [accessed 2021 June].

REACH [Registration, Evaluation, Authorisation and Restriction of Chemicals]. 2020. Registration (REACH) dossier for Tellurium dioxide (CASRN 7446-07-3). First published: 09-Feb-2015. Last modified: 11-Mar-2020. [accessed 2021 June]. [RIVM] Rijksinstituut voor Volksgezondheid en Milieu (National Institute for Public Health and the Environment). 1998. Maximum Permissible Risk Levels for Human Intake of Soil Contaminants: Fourth Series of Compounds.

Roels HA, Buchet JP. 2001. Determination of germanium in urine and its usefulness for biomonitoring of inhalation exposure to inorganic germanium in the occupational setting. *J Environ Monit.* 3:67-73.

Rosenfeld G. 1954. Studies of the metabolism of germanium. *Arch Biochem. Biophys.* 48:84-94.

Rust, KF., and Rao, JNK. 1996. Variance estimation for complex surveys using replication techniques. *Statistical Methods in Medical Research*, 5: 283-310.

Schroeder HA, Buckman J, Balassa JJ. 1967. Abnormal trace elements in man: tellurium. *J Chronic Dis.* 20(3):147-161.

Shinogi M, Masaki T. and Mori I. (1989). Determination and biokinetics of germanium in mouse tissues by atomic absorption spectrometry with electrothermal atomization. *J Trace Elem Electrolytes Health Dis.* 3:25-28.

Shire Pharmaceutical Contract Ltd. 2012. Product information. Fosrenol. 2004. Lanthanum carbonate hydrate. United Kingdom.

Slikkerveer A, de Wolff FA. 1989. Pharmacokinetics and toxicity of bismuth compounds. *Med Toxicol Adverse Drug Exp.* 4(5):303-323.

Tao SH, Bolger PM. 1997. Hazard assessment of germanium supplements. *Reg toxicol pharmacol.* 25: 211-219.

Tugulea AM et al. 2016. National survey of disinfection by-products and selected drinking water contaminants in Canadian drinking water (2009-2010). Unpublished database. Ottawa (ON): Exposure and Biomonitoring Division, Health Canada.

US EPA [United States Environmental Protection Agency]. 2009a. Toxicological review of cerium oxide and cerium compounds. US Environmental Protection Agency, Washington, DC, EPA/635/R-08/002F.

US EPA [United States Environmental Protection Agency]. 2009b. Provisional Peer Reviewed Toxicity Values for Stable (Nonradioactive) Neodymium Chloride [PDF]. Office of Research and Development. Cincinnati, OH. [accessed 2019 October]

US EPA [United States Environmental Protection Agency]. 2009c. Provisional Peer Reviewed Toxicity Values for Stable (Nonradioactive) Praseodymium Chloride [PDF]. Office of Research and Development. Cincinnati, OH. [accessed 2019 October]

US EPA [United States Environmental Protection Agency]. 2008. Provisional Peer Reviewed Toxicity Values for Lithium (CASRN 7439-93-2). [PDF] Superfund Health Risk Technical Support Center National Center for Environmental Assessment Office of Research and Development U.S. Environmental Protection Agency. Cincinnati

US FDA [US Food and Drug administration]. 2004. Drug approval package, Fosrenol®(Lanthanum carbonate) tablets. [accessed August 2019].

US EPA [United States United States Environmental Protection Agency]. 2018. Provisional Peer-Reviewed Toxicity Values for Lanthanum [PDF]. [accessed 2019 October]

US FDA [US Food and Drug administration]. 2018. Miscellaneous drug products for over the counter human use. Deodorant drug products for internal use (for products containing bismuth subgallate). [accessed 2019 August].

US HPD [United States Household Product database]. 2017. Health and safety information on household products. [accessed April 2017].

Valencia R, Mason RM, Woodruff RC, Zimmering Z. 1985. Chemical mutagenesis testing in *Drosophila*: III. Results of 48 coded compounds tested for the National Toxicology Program. *Environ Mutagen*. 7: 325-348.

Ward ME, Musa MN, Bailey L. 1994. Clinical pharmacokinetics of lithium. *J Clin Pharmacol*. 34(4):280-285.

Wenzel WJ, Thomas RG, McClellan RO. 1969. Effect of stable yttrium concentration on the distribution and excretion of inhaled radioyttrium in the rat. *Am Ind Hyg Assoc J*. 30(6):630-634.

Yokel RA, Hussain S, Garantzotis S, Demokritou P, Castranova V, Cassee FR. 2014. The yin: an adverse health perspective of nanoceria: uptake, distribution, accumulation, and mechanisms of its toxicity. *Environ. Sci.: Nano*. 1: 406-428.

Appendix A. List of substances and assessment approaches

Table A-1. List of substances and approaches used in this screening assessment

CAS-RN	DSL name	Common name	Ecological approach	Human health approach
56797-01-4	Hexanoic acid, 2-ethyl-, cerium(3+) salt	Cerium (III) 2-ethylhexanoate	ERC-I	Biomonitoring Approach 1
10038-98-9	Germane, tetrachloro-	Germanium (IV) Chloride	ERC-I	Biomonitoring Approach 1
1312-81-8	Lanthanum oxide (La ₂ O ₃)	Lanthanum (III) oxide	ERC-I	Biomonitoring Approach 1
10099-58-8	Lanthanum chloride (LaCl ₃)	Lanthanum (III) chloride	ERC-I	Biomonitoring Approach 1
12008-21-8	Lanthanum boride (LaB ₆), (OC-6-11)-	Lanthanum hexaboride	ERC-I	Biomonitoring Approach 1
73227-23-3	Hexanoic acid, 2-ethyl-, neodymium(3+) salt	Neodymium 2-ethylhexanoate	ERC-I	Biomonitoring Approach 1
12036-32-7	Praseodymium oxide (Pr ₂ O ₃)	Praseodymium oxide	ERC-I	Biomonitoring Approach 1
7446-07-3	Tellurium oxide (TeO ₂)	Tellurium dioxide	ERC-I	Biomonitoring Approach 1
20941-65-5	Tellurium, tetrakis(diethylcarbamodithioato-S,S')-, (DD-8-111"1"1'1'1"1"1")-	Ethyl tellurac	ERC-I	Biomonitoring Approach 1
1314-36-9	Yttrium oxide (Y ₂ O ₃)	Yttrium oxide	ERC-I	Biomonitoring Approach 1
1304-76-3	Bismuth oxide (Bi ₂ O ₃)	Bismuth (III) oxide	ERC-I	Biomonitoring Approach 2
1304-85-4	Bismuth hydroxide nitrate oxide (Bi ₅ (OH) ₉ (NO ₃) ₄ O)	Bismuth subnitrate	ERC-I	Biomonitoring Approach 2
10361-44-1	Nitric acid, bismuth(3+) salt	Bismuth (III) nitrate	ERC-I	Biomonitoring Approach 2
14059-33-7	Bismuth vanadium oxide (BiVO ₄)	Bismuth vandate (V)	ERC-I	Biomonitoring Approach 2
21260-46-8	Bismuth, tris(dimethylcarbam	Bismuth Dimethyldithiocarbamate	ERC-I	Biomonitoring Approach 2

CAS-RN	DSL name	Common name	Ecological approach	Human health approach
	odithioato-S,S')-, (OC-6-11)-			
34364-26-6	Neodecanoic acid, bismuth(3+) salt	Bismuth Neodecanoate	ERC-I	Biomonitoring Approach 2
67874-71-9	Hexanoic acid, 2-ethyl-, bismuth(3+) salt	Bismuth 2-ethylhexanoate	ERC-I	Biomonitoring Approach 2
546-89-4	Acetic acid, lithium salt	Lithium acetate	ERC-I	Biomonitoring Approach 2
554-13-2	Carbonic acid, dilithium salt	Lithium carbonate	ERC-I	Biomonitoring Approach 2
1310-65-2	Lithium hydroxide (Li(OH))	Lithium Hydroxide	ERC-I	Biomonitoring Approach 2
4485-12-5	Octadecanoic acid, lithium salt	Lithium stearate	ERC-I	Biomonitoring Approach 2
7439-93-2	Lithium	NA	ERC-I	Biomonitoring Approach 2
7447-41-8	Lithium chloride (LiCl)	NA	ERC-I	Biomonitoring Approach 2
7620-77-1	Octadecanoic acid, 12-hydroxy-, monolithium salt	Lithium 12-hydroxystearate	ERC-I	Biomonitoring Approach 2
7789-24-4	Lithium fluoride (LiF)	NA	ERC-I	Biomonitoring Approach 2
10377-48-7	Sulfuric acid, dilithium salt	Lithium sulfate	ERC-I	Biomonitoring Approach 2
12627-14-4	Silicic acid, lithium salt	Lithium polysilicate	ERC-I	Biomonitoring Approach 2
13840-33-0	Hypochlorous acid, lithium salt	Lithium Hypochlorite	ERC-I	Biomonitoring Approach 2
27253-30-1	Neodecanoic acid, lithium salt	Lithium neodecanoate	ERC-I	Biomonitoring Approach 2
38900-29-7	Nonanedioic acid, dilithium salt	Dilithium azelate	ERC-I	Biomonitoring Approach 2
53320-86-8	Silicic acid, lithium magnesium sodium salt	Lithium magnesium sodium silicate	ERC-I	Biomonitoring Approach 2
68649-48-9	Paraffin waxes and Hydrocarbon waxes, oxidized, lithium salts	NA	ERC-I	Biomonitoring Approach 2

CAS-RN	DSL name	Common name	Ecological approach	Human health approach
68783-37-9	Fatty acids, C16-18, lithium salts	NA	ERC-I	Biomonitoring Approach 2
7789-38-0	Bromic acid, Sodium salt	Sodium bromate	ERC-I	Rapid Screening for Substances with Limited General Population Exposure

Abbreviations: NA = not available, ERC-I = Ecological Risk Classification of Inorganic Substances

Appendix B. ERC-I classifications for the 34 substances addressed in this screening assessment

Table B-1. ERC-I classifications for the 34 substances addressed in this screening assessment

CAS RN	DSL name	ERC-I Predictive Modelling Ranking	ERC-I Water Quality Monitoring Ranking	Overall ERC-I Classification
56797-01-4	Hexanoic acid, 2-ethyl-, cerium(3+) salt	Low	Low	Low
10038-98-9	Germane, tetrachloro-	Low	NA	Low
1312-81-8	Lanthanum oxide (La_2O_3)	Moderate	Low	Low
10099-58-8	Lanthanum chloride (LaCl_3)	Moderate	Low	Low
12008-21-8	Lanthanum boride, (OC-6-11)-	Moderate	Low	Low
7446-07-03	Tellurium oxide	Low	Low	Low
20941-65-5	Tellurium, tetrakis(diethylcarbamodithioato-S,S')-, (DD-8-111''1''1'1'1'''1''')-	Low	Low	Low
73227-23-3	Hexanoic acid, 2-ethyl-, neodymium(3+) salt	Low	Low	Low
12036-32-7	Praseodymium oxide (Pr_2O_3)	Low	Low	Low
1314-36-9	Yttrium oxide (Y_2O_3)	Moderate	Low	Low
1304-76-3	Bismuth oxide	Low	Low	Low
1304-85-4	Bismuth hydroxide nitrate oxide ($\text{Bi}_5(\text{OH})_9(\text{NO}_3)_4\text{O}$)	Low	Low	Low
14059-33-7	Bismuth vanadium oxide (BiVO_4)	Low	Low	Low
10361-44-1	Nitric acid, bismuth(3+) salt	Low	Low	Low
21260-46-8	Bismuth, tris(dimethylcarbamodithioato-S,S')-, (OC-6-11)-	Low	Low	Low
34364-26-6	Neodecanoic acid, bismuth(3+) salt	Low	Low	Low
67874-71-9	Hexanoic acid, 2-ethyl-, bismuth(3+) salt	Low	Low	Low

546-89-4	Acetic acid, lithium salt	Low	Low	Low
554-13-2	Carbonic acid, dilithium salt	Low	Low	Low
1310-65-2	Lithium hydroxide (Li(OH))	Low	Low	Low
4485-12-05	Octadecanoic acid, lithium salt	Low	Low	Low
7439-93-2	Lithium	Low	Low	Low
7447-41-8	Lithium chloride (LiCl)	Low	Low	Low
7620-77-1	Octadecanoic acid, 12-hydroxy-, monolithium salt	Low	Low	Low
7789-24-4	Lithium fluoride (LiF)	Low	Low	Low
10377-48-7	Sulfuric acid, dilithium salt	Low	Low	Low
12627-14-4	Silicic acid, lithium salt	Low	Low	Low
13840-33-0	Hypochlorous acid, lithium salt	Low	Low	Low
27253-30-1	Neodecanoic acid, lithium salt	Low	Low	Low
38900-29-7	Nonanedioic acid, dilithium salt	Low	Low	Low
53320-86-8	Silicic acid, lithium magnesium sodium salt	Low	Low	Low
68649-48-9	Paraffin waxes and Hydrocarbon waxes, oxidized, lithium salts	Low	Low	Low
68783-37-9	Fatty acids, C16-18, lithium salts	Low	Low	Low
7789-38-0	Bromic acid, sodium salt	Low	NA	Low

Abbreviations: NA =, not available

Appendix C. Median air and house dust concentrations of elements

Table C-1. Median concentrations of elements in air PM_{2.5} (ng/m³) and house dust µg/g)

Element	Indoor air	Personal air (PM _{2.5}) ¹	Outdoor air (PM _{2.5}) ¹	Outdoor air (PM _{2.5}) ²	Dust Data (µg/g) ^{1,3}
Bismuth	PM _{2.5} = 0.06 (n=437) ¹	0.07 (n=445)	0.21 (n=447)	NA	2.42
Cerium	PM ₁₀ = 0.37 (modelled) ⁴	NA	NA	0.030 (n=969)	24.7
Germanium	PM ₁₀ = 0.001 (modelled) ⁴	NA	NA	NA	<0.1
Lanthanum	PM ₁₀ = 0.19 (modelled) ⁴	NA	NA	0.028 (n=969)	12.7
Lithium	PM _{2.5} <0.08 (n=37) ¹	<0.08 (n=38)	0.11 (n=38)	NA	6.5
Neodymium	PM ₁₀ = 0.13 (modelled) ⁴	NA	NA	NA	8.6
Praseodymium	PM ₁₀ = 0.04 (modelled) ⁴	NA	NA	NA	2.8
Tellurium	PM ₁₀ = 0.003 (modelled) ⁴	NA	NA	NA	0.18
Yttrium	PM ₁₀ = 0.07 (modelled) ⁴	NA	NA	NA	4.6

Abbreviations: NA = not applicable; PM_{2.5} = particulate matter less than or equal to 2.5 microns; PM₁₀ = particulate matter less than or equal to 10 microns.

¹ Rasmussen 2017; ² NAPS 2015; ³Rasmussen et al. 2017; ⁴ Rasmussen 2019